| NCT04341545 | Queen Mary Hospital, Hong Kong|Kwong Wah Hospital|Princess Margaret Hospital, Hong Kong|Pamela Youde Nethersole Eastern Hospital, Hong Kong|Queen Elizabeth Hospital, Hong Kong|Prince of Wales Hospital, Shatin, Hong Kong | Tubal Pregnancy | 2020-12-01 | PHASE3 |
| NCT01127295 | Institut Claudius Regaud | Hormono-depending Adjuvant Breast Cancer | 2010-06-17 | PHASE4 |
| NCT00648154 | Mylan Pharmaceuticals Inc | Healthy | 2005-11 | PHASE1 |
| NCT00237133 | Novartis Pharmaceuticals | Locally Advanced Breast Cancer | 2003-03 | PHASE4 |
| NCT02958852 | Lund University Hospital|South Sweden Breast Cancer Group | Breast Cancer | 2025-01-02 | PHASE2 |
| NCT03671330 | Novartis Pharmaceuticals | Breast Cancer | 2018-08-29 | PHASE2 |
| NCT05851014 | Genor Biopharma Co., Ltd. | Breast Cancer | 2022-01-14 | PHASE3 |
| NCT04095364 | NRG Oncology|National Cancer Institute (NCI) | Low Grade Fallopian Tube Serous Adenocarcinoma|Ovarian Low Grade Serous Adenocarcinoma|Primary Peritoneal Low Grade Serous Adenocarcinoma|Stage II Fallopian Tube Cancer AJCC v8|Stage II Ovarian Cancer AJCC v8|Stage II Primary Peritoneal Cancer AJCC v8|Stage III Fallopian Tube Cancer AJCC v8|Stage III Ovarian Cancer AJCC v8|Stage III Primary Peritoneal Cancer AJCC v8|Stage IV Fallopian Tube Cancer AJCC v8|Stage IV Ovarian Cancer AJCC v8|Stage IV Primary Peritoneal Cancer AJCC v8 | 2019-09-20 | PHASE3 |
| NCT04856371 | Haihe Biopharma Co., Ltd. | Advanced Breast Cancer | 2021-04 | PHASE1 |
| NCT05512364 | European Organisation for Research and Treatment of Cancer - EORTC|Breast International Group|Menarini Group | ER-positive Breast Cancer|HER2-negative Breast Cancer|Stage IIB Breast Cancer|Stage III Breast Cancer | 2023-12-15 | PHASE3 |
| NCT01153672 | University of Washington|National Cancer Institute (NCI) | Male Breast Cancer|Recurrent Breast Cancer|Stage IV Breast Cancer | 2010-11 | NA |
| NCT00688194 | Gruppo Italiano Mammella (GIM) | Breast Cancer | 2008-05 | PHASE3 |
| NCT05085002 | EQRx, Inc. | Advanced Breast Cancer | 2021-12-21 | PHASE2 |
| NCT00719186 | Yale University|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)|Penn State University|University of Colorado, Denver|University of Michigan|University of Pennsylvania|The University of Texas Health Science Center at San Antonio|University of Vermont|Wayne State University | Pregnancy|Polycystic Ovary Syndrome | 2009-02 | PHASE3 |
| NCT00414076 | M.D. Anderson Cancer Center|Novartis | Leiomyosarcoma|Uterine Neoplasm | 2006-12-19 | PHASE2 |
| NCT06006091 | International Peace Maternity and Child Health Hospital | Letrozole|Infertility, Female | 2023-08-01 | NA |
| NCT07492641 | BeOne Medicines | HR&addition;+HER2- Breast Cancer | 2026-05-11 | PHASE3 |
| NCT06861803 | Al-Azhar University | PCOS (Polycystic Ovary Syndrome) of Bilateral Ovaries | 2025-04-01 | |
| NCT00097344 | Intarcia Therapeutics | Breast Neoplasms|Neoplasms, Hormone-Dependent | 2004-12 | PHASE3 |
| NCT01669343 | Samuel Lunenfeld Research Institute, Mount Sinai Hospital | Breast Neoplasms | 2012-10 | NA |
| NCT05316935 | Xiaojun Chen | Endometrial Neoplasms|Atypical Endometrial Hyperplasia|Progesterone Resistance | 2022-07-13 | PHASE2|PHASE3 |
| NCT05163106 | University Hospital, Akershus|Novartis|Vestre Viken Hospital Trust | Breast Cancer|HER2-negative Breast Cancer|ER-positive Breast Cancer|Locally Advanced Breast Cancer|Luminal A Breast Cancer|Luminal B Breast Cancer | 2022-12-01 | PHASE2 |
| NCT06793904 | Cairo University | Polycystic Ovarian Syndrome (PCOS) | 2025-02-01 | NA |
| NCT00579826 | Carol Fabian, MD|Novartis|National Cancer Institute (NCI) | Breast Cancer | 2006-10 | PHASE2 |
| NCT05512416 | The Affiliated Hospital of Qingdao University|Jiangsu HengRui Medicine Co., Ltd. | Breast Cancer | 2022-08 | PHASE2 |
| NCT04002141 | University of California, San Francisco | Endometriosis|Ovarian Hyperstimulation | 2019-09-17 | PHASE2 |
| NCT06671912 | Alliance for Clinical Trials in Oncology|National Cancer Institute (NCI) | Anatomic Stage 0 Breast Cancer AJCC v8|Anatomic Stage 1 Breast Cancer AJCC v8|Anatomic Stage IIA Breast Cancer AJCC v8|Estrogen Receptor-Positive Breast Carcinoma|HER2-Negative Breast Carcinoma | 2025-02-19 | PHASE3 |
| NCT05439499 | Ahon Pharmaceutical Co., Ltd. | Advanced Breast Cancer|Female Breast Cancer | 2022-03-02 | PHASE3 |
| NCT00114270 | University of Virginia|National Cancer Institute (NCI) | Breast Cancer|Osteoporosis | 2004-05 | NA |
| NCT02764541 | Dana-Farber Cancer Institute|Pfizer | Breast Cancer | 2016-05-24 | PHASE2 |
| NCT06348134 | University of Chicago | Human Epidermal Growth Factor 2 Negative Carcinoma of Breast|HER2-positive Breast Cancer|Breast Cancer | 2025-03-18 | PHASE2 |
| NCT01219153 | Cairo University|Ahmed Elgazzar Hospital | Infertility | 2008-09 | PHASE2 |
| NCT05183828 | University of Washington|National Cancer Institute (NCI) | Anatomic Stage I Breast Cancer AJCC v8|Anatomic Stage II Breast Cancer AJCC v8|Anatomic Stage III Breast Cancer AJCC v8|Breast Adenocarcinoma|Invasive Breast Carcinoma of No Special Type | 2022-01-23 | PHASE4 |
| NCT04111978 | Swiss GO Trial Group|AGO Study Group|Arbeitsgemeinschaft Gynaekologische Onkologie Austria|Reliable Cancer Therapies|Krebsliga Schweiz|Stiftung Guido Feger|Hoffmann-La Roche|Helsana AG|Novartis Pharmaceuticals|Anticancer Fund, Belgium | Ovarian Neoplasm Epithelial|Fallopian Tube Neoplasms|Peritoneal Neoplasms|High-grade Serous Ovarian Carcinoma (HGSOC)|Low-grade Serous Ovarian Carcinoma (LGSOC)|Ovarian Endometrioid Carcinoma | 2020-11-05 | PHASE3 |
| NCT05166668 | Menoufia University | Ovarian Stimulation | 2021-11-01 | NA |
| NCT03011684 | University of California, San Francisco | Infertility | 2016-07-21 | PHASE3 |
| NCT00305825 | University of California, San Francisco|National Cancer Institute (NCI)|Memorial Sloan Kettering Cancer Center | Breast Cancer | 2004-08 | PHASE2 |
| NCT07274709 | Shirley Vichy Wang|Food and Drug Administration (FDA) | Advanced Breast Cancer | 2025-09-07 | |
| NCT02344550 | Asan Medical Center | Metastatic Breast Cancer | 2014-01 | PHASE2 |
| NCT00310180 | National Cancer Institute (NCI)|American College of Surgeons|Cancer and Leukemia Group B|NSABP Foundation Inc|NCIC Clinical Trials Group|North Central Cancer Treatment Group|SWOG Cancer Research Network | Breast Adenocarcinoma|Hormone Receptor Positive|Stage IA Breast Cancer AJCC v7|Stage IB Breast Cancer AJCC v7|Stage IIA Breast Cancer AJCC v6 and v7|Stage IIB Breast Cancer AJCC v6 and v7|Stage IIIB Breast Cancer AJCC v7 | 2006-04-07 | PHASE3 |
| NCT03122197 | University of Cincinnati | Brain Tumor | 2017-05-16 | EARLY_PHASE1 |
| NCT00237224 | Novartis Pharmaceuticals | Breast Cancer | 2003-02 | PHASE4 |
| NCT01698918 | Novartis Pharmaceuticals | Hormone Receptor Positive Breast Cancer | 2013-03-07 | PHASE2 |
| NCT07288359 | Novartis Pharmaceuticals | Advanced HR&addition;+HER2- Breast Cancer|Advanced CCNE1-amplified Solid Tumors|Metastatic Castration-resistant Prostate Cancer | 2025-12-29 | PHASE1|PHASE2 |
| NCT01499160 | University of Maryland, Baltimore|Novartis Pharmaceuticals|GlaxoSmithKline | Breast Neoplasms|Endocrine Breast Diseases|Neoplasm Metastasis | 2012-05 | PHASE2 |
| NCT02648477 | City of Hope Medical Center|National Cancer Institute (NCI)|Merck Sharp & Dohme LLC | Estrogen Receptor Negative|Estrogen Receptor Positive|HER2+Neu Negative|Progesterone Receptor Negative|Progesterone Receptor Positive|Stage IV Breast Cancer|Triple-Negative Breast Carcinoma | 2016-03-28 | PHASE2 |
| NCT03272477 | Palleos Healthcare GmbH|Roche Pharma AG|WSG WOMEN?S HEALTHCARE STUDY GROUP|Cankado GmbH | Breast Neoplasms | 2017-10-05 | PHASE2 |
| NCT02273973 | Genentech, Inc.|SOLTI Breast Cancer Research Group|Breast International Group|Austrian Breast & Colorectal Cancer Study Group | Breast Cancer | 2014-11-12 | PHASE2 |
| NCT05514054 | Eli Lilly and Company | Breast Neoplasms | 2022-10-04 | PHASE3 |
| NCT04895761 | Providence Health & Services | Breast Cancer | 2021-09-10 | PHASE1 |
| NCT02712723 | Qamar Khan|Novartis Pharmaceuticals | Breast Cancer | 2016-02 | PHASE2 |
| NCT01780610 | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | Infertility | 2012-01 | NA |
| NCT07425990 | University of Novi Sad | Infertility Female|Frozen Embryo Transfer (FET) | 2026-02 | NA |
| NCT00945360 | American University of Beirut Medical Center | Symptomatic or Large Uterine Fibroids | 2011-03 | PHASE1 |
| NCT00084396 | Washington University School of Medicine|National Cancer Institute (NCI) | Breast Cancer | 2003-10 | PHASE2 |
| NCT00333047 | Novartis | Metastatic Breast Cancer | 2002-07 | PHASE2|PHASE3 |
| NCT02115048 | Translational Research in Oncology|Boehringer Ingelheim | Breast Neoplasms | 2014-07 | PHASE2 |
| NCT01989780 | Japan Breast Cancer Research Group|Chugai Pharmaceutical | Metastatic Breast Cancer | 2014-01 | PHASE2 |
| NCT03181919 | Benha University | Infertility Poly Cystic Ovary | 2016-01-01 | NA |
| NCT00478504 | University of Nottingham|University Hospitals of Derby and Burton NHS Foundation Trust | Infertility|Polycystic Ovarian Syndrome | 2007-05 | PHASE4 |
| NCT07109947 | Aswan University | Miscarriage | 2025-07-10 | NA |
| NCT02701348 | NHS Tayside | Breast Cancer | 2016-05 | NA |
| NCT01431352 | Heilongjiang University of Chinese Medicine | Polycystic Ovary Syndrome | 2009-09 | NA |
| NCT05712941 | EQRx International, Inc.|GOG Foundation|European Network of Gynaecological Oncological Trial Groups (ENGOT) | Endometrial Carcinoma | 2023-04-18 | PHASE3 |
| NCT00412022 | National Cancer Institute, Naples|University of Campania Luigi Vanvitelli | Breast Cancer | 2004-03 | PHASE3 |
| NCT01740427 | Pfizer | Breast Neoplasms | 2013-02-22 | PHASE3 |
| NCT01315912 | Bushehr University of Medical Science | Infertility | 2008-01 | PHASE4 |
| NCT04316169 | Medical College of Wisconsin | Solid Tumor|Advanced Breast Cancer | 2021-10-21 | PHASE1 |
| NCT03839823 | Novartis Pharmaceuticals | Breast Cancer | 2019-02-25 | PHASE2 |
| NCT04886531 | Ruth O´Regan|Puma Biotechnology, Inc.|University of Rochester | Breast Cancer|HER2-positive Breast Cancer|ER Positive Breast Cancer|PR-Positive Breast Cancer | 2022-07-21 | PHASE2 |
| NCT04834791 | Tanta University | Clomiphene Citrate Resistance|Ovulation Induction|Letrozole|Gonadotropins | 2019-03-01 | PHASE4 |
| NCT00146146 | Unita Complessa di Ostetricia e Ginecologia|Schering-Plough | Transsexualism | 2005-05 | PHASE3 |
| NCT02491320 | The First Affiliated Hospital of Guangzhou Medical University|The University of Hong Kong|Karolinska Institutet|Xuzhou Maternity and Child Health Care Hospital|Hexian Memorial Affiliated Hospital of Southern Medical University | Polycystic Ovary Syndrome | 2015-08 | PHASE3 |
| NCT00240942 | Novartis Pharmaceuticals | Severe and Recurrent Endometriosis | 2002-10 | PHASE2 |
| NCT03248427 | SOLTI Breast Cancer Research Group|Novartis | Breast Cancer | 2017-07-13 | PHASE2 |
| NCT02585388 | ARCAGY+ GINECO GROUP|Pierre Fabre Laboratories | Breast Cancer | 2015-10-23 | PHASE2 |
| NCT05168865 | Dubai Fertility Center | Frozen Embryo Transfer|Polycystic Ovarian Disease|Letrozole|Hormone Replacement Therapy|Live Birth|Miscarriage | 2023-08-01 | PHASE4 |
| NCT03458221 | Gynaecologisch Oncologisch Centrum Zuid|Radboud University Medical Center|Erasmus Medical Center|Maastricht University Medical Center|InnoSIGN|Eurofins | Recurrent Ovarian Cancer|Signal Transduction Pathway Deregulation|Therapy-Associated Cancer | 2023-01-31 | PHASE2|PHASE3 |
| NCT00267553 | Intarcia Therapeutics | Breast Neoplasms|Neoplasms, Hormone-Dependent | 2005-11 | PHASE3 |
| NCT03050398 | Novartis Pharmaceuticals | Breast Cancer | 2017-06-07 | PHASE3 |
| NCT00171847 | Novartis Pharmaceuticals|Roche - Prof. Dr. Jens Huober et al. | Metastatic Breast Cancer | 2003-03 | PHASE4 |
| NCT01218581 | Mansoura University | the Efficacy of Aromatase Inhibitor vs. Gonadotrpins Releasing Hormone Agonists in Treating Premenopausal Women With Uterine Adenomyosis | 2005-12 | PHASE2|PHASE3 |
| NCT02802865 | Rachel Mejia | Polycystic Ovary Syndrome|Infertility | 2016-08 | PHASE4 |
| NCT02304107 | Cairo University | Infertility | 2013-05 | PHASE3 |
| NCT03220178 | Palleos Healthcare GmbH|WSG WOMEN?S HEALTHCARE STUDY GROUP|Cankado GmbH|Pfizer|AGO-TraFo|AGO-B|Deutsche Gesellschaft für H?matologie und Medizinische Onkologie e.V. | Breast Neoplasm | 2017-07-24 | PHASE4 |
| NCT01791985 | Imperial College London|Cancer Research UK|AstraZeneca | Breast Cancer | 2012-07 | PHASE1|PHASE2 |
| NCT06930859 | Novartis Pharmaceuticals | Breast Cancer | 2025-12-22 | |
| NCT00014638 | Novartis | Breast Cancer | 2001-01 | PHASE4 |
| NCT00867217 | Qamar Khan|Novartis Pharmaceuticals|BTR Group | Breast Cancer | 2009-03 | PHASE2 |
| NCT01082068 | Sanofi | Breast Cancer | 2010-06 | PHASE1|PHASE2 |
| NCT07054190 | Hoffmann-La Roche | Breast Cancer | 2025-09-09 | PHASE2 |
| NCT03099174 | Boehringer Ingelheim | Neoplasms|Breast Neoplasms | 2017-05-04 | PHASE1 |
| NCT06179303 | University of Washington|Breast Cancer Research Foundation | Anatomic Stage III Breast Cancer AJCC v8|Anatomic Stage IV Breast Cancer AJCC v8|Locally Advanced Unresectable HER2-Negative Breast Carcinoma|Locally Advanced Unresectable Hormone Receptor-Positive Breast Carcinoma|Metastatic HER2-Negative Breast Carcinoma|Metastatic Hormone Receptor-Positive Breast Carcinoma | 2024-07-22 | PHASE2 |
| NCT01709370 | Organisation for Oncology and Translational Research | ER Positive, HER2 Negative Breast Cancer | 2012-02 | PHASE2 |
| NCT01674140 | SWOG Cancer Research Network|National Cancer Institute (NCI) | Breast Cancer | 2013-09-12 | PHASE3 |
| NCT06555068 | Jiangsu HengRui Medicine Co., Ltd. | Advanced Unresectable or Metastatic Breast Cancer | 2024-08-12 | PHASE1|PHASE2 |
| NCT04906395 | Tolmar Inc. | Breast Cancer | 2021-07-01 | PHASE3 |
| NCT06706414 | Martin Blomberg Jensen | Infertility, Male | 2025-03-01 | PHASE1|PHASE2 |
| NCT02401425 | Ain Shams University | Complete Miscarriage | 2015-03 | PHASE2|PHASE3 |
| NCT00330317 | Novartis Pharmaceuticals | Breast Cancer | 2006-02 | PHASE3 |
| NCT00208273 | Institut du Cancer de Montpellier - Val d´Aurelle|Novartis | Breast Cancer | 2005-01 | PHASE2 |
| NCT02093351 | AstraZeneca | Solid Tumours | 2014-09-01 | PHASE1 |
| NCT03747042 | University of Texas Southwestern Medical Center|Cancer Prevention Research Institute of Texas | Breast Cancer Female | 2018-11-27 | PHASE2 |
| NCT04282031 | Beta Pharma (Suzhou) Co., Ltd. | Advanced Solid Tumor|HR&addition;+HER2- Breast Cancer | 2020-06-15 | PHASE1|PHASE2 |
| NCT05228951 | Shengjing Hospital | Breast Cancer | 2022-02-10 | PHASE2 |
| NCT05341817 | KK Women´s and Children´s Hospital | Abortion in First Trimester | 2022-11-22 | PHASE4 |
| NCT04321551 | University of California, San Diego | Transgender|Healthy | 2023-07-01 | PHASE4 |
| NCT02188745 | Dartmouth-Hitchcock Medical Center | Metastatic Breast Cancer | 2016-03-11 | PHASE2 |
| NCT06570031 | Ono Pharmaceutical Co., Ltd. | Hormone Receptor-positive Breast Cancer|HER2-negative Breast Cancer|Metastatic Breast Cancer|Recurrent Breast Cancer | 2021-11-09 | PHASE1 |
| NCT00963729 | Imperial College London | Breast Cancer | 2008-09 | PHASE3 |
| NCT00101062 | University of Medicine and Dentistry of New Jersey|National Cancer Institute (NCI) | Breast Cancer | 2004-01 | PHASE2 |
| NCT02624973 | Haukeland University Hospital|Helse Vest|Pfizer|AstraZeneca | Breast Cancer | 2016-04-15 | PHASE2 |
| NCT02689921 | Midwestern Regional Medical Center | Breast Neoplasms | 2016-04 | PHASE2 |
| NCT04568616 | Dartmouth-Hitchcock Medical Center | Breast Cancer|ER Positive Breast Cancer | 2021-08-13 | PHASE2 |
| NCT03497702 | National Cancer Center, Korea | Breast Cancer|Invasive Breast Cancer | 2017-05-08 | PHASE2 |
| NCT04191382 | Sanofi | Breast Cancer | 2020-02-04 | PHASE2 |
| NCT07024173 | Shandong Suncadia Medicine Co., Ltd. | Locally Advanced Breast Cancer|Metastatic Breast Cancer | 2025-07-23 | PHASE3 |
| NCT03024580 | Instituto Nacional de Cancer, Brazil|Cancer Research UK Cambridge Institute | Breast Neoplasm | 2017-03-06 | PHASE2 |
| NCT02294773 | Midwest Fertility Specialists | Infertility | 2013-10 | NA |
| NCT02377479 | University Hospitals Cleveland Medical Center | Infertility | 2015-03 | NA |
| NCT05800756 | Yantai Yuhuangding Hospital|Jiangsu Hengrui Pharmaceutical Co., Ltd. | Breast Cancer | 2022-08-04 | PHASE2 |
| NCT06974929 | Jiangsu HengRui Medicine Co., Ltd. | Breast Cancer | 2025-05-22 | PHASE1|PHASE2 |
| NCT02742051 | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | Breast Cancer | 2016-06 | PHASE2 |
| NCT06253195 | BeiGene | Advanced Solid Tumor|Metastatic Solid Tumor|Hormone-receptor-positive Breast Cancer|Breast Cancer|Metastatic Breast Cancer|Hormone Receptor Positive Malignant Neoplasm of Breast|HER2-negative Breast Cancer | 2024-04-01 | PHASE1 |
| NCT00505661 | M.D. Anderson Cancer Center | Ovarian Cancer|Fallopian Tube Cancer|Peritoneal Cancer | 2003-09 | PHASE2 |
| NCT02619669 | Gary Schwartz | Breast Cancer | 2017-04-20 | PHASE1 |
| NCT04931342 | Hoffmann-La Roche|GOG Foundation|European Network of Gynaecological Oncological Trial Groups (ENGOT) | Ovarian Cancer | 2021-10-07 | PHASE2 |
| NCT01077453 | National Cancer Institute (NCI) | Healthy, no Evidence of Disease|Lobular Breast Carcinoma in Situ | 2010-03 | PHASE1 |
| NCT05847257 | Al-Mustansiriyah University|Al-Nahrain University | Male Reproductive Problem|Infertility, Male | 2021-12-01 | PHASE2 |
| NCT05827081 | Novartis Pharmaceuticals | Early Breast Cancer | 2024-02-28 | PHASE3 |
| NCT02583828 | Capital Medical University | Breast Neoplasms|Neoplasm Metastasis | 2015-06 | NA |
| NCT07570966 | Novartis Pharmaceuticals | Advanced HR&addition;+HER2- Breast Cancer|Advanced CCNE1-amplified Solid Tumors|Metastatic Castration-resistant Prostate Cancer (mCRPC) | 2026-06-30 | PHASE1|PHASE2 |
| NCT01999569 | Wake Forest University Health Sciences | Ovulation Disorder|Ovarian Cysts | 2007-04 | PHASE4 |
| NCT06346457 | International Research Training Group 2804|German Research Foundation|University Hospital Tuebingen|Uppsala University | Breast Cancer Female|Healthy Female|Menopause|Anti-estrogenic Therapy | 2024-04-01 | |
| NCT05307705 | Eli Lilly and Company | Breast Cancer | 2022-05-11 | PHASE1 |
| NCT03397537 | Guangdong Provincial People´s Hospital | Highly Endocrine Responsive Operable Breast Cancer | 2012-09 | PHASE2 |
| NCT00696072 | Bristol-Myers Squibb|US Oncology Research | Metastatic Breast Cancer | 2008-08 | PHASE2 |
| NCT04256941 | M.D. Anderson Cancer Center|National Cancer Institute (NCI) | Anatomic Stage IV Breast Cancer AJCC v8|Metastatic Breast Carcinoma|Prognostic Stage IV Breast Cancer AJCC v8 | 2019-05-31 | PHASE2 |
| NCT07391774 | National Cancer Institute (NCI) | Anatomic Stage II Breast Cancer AJCC v8|Anatomic Stage IIIA Breast Cancer AJCC v8|Anatomic Stage IIIC Breast Cancer AJCC v8|Estrogen Receptor-Positive Breast Carcinoma|HER2-Negative Breast Carcinoma | 2026-07-07 | PHASE3 |
| NCT00134680 | Duke University|Genentech, Inc.|Novartis Pharmaceuticals | Metastatic Breast Cancer | 2000-01 | PHASE2 |
| NCT00844350 | Tabriz University | Ovarian Response | 2006-10 | PHASE2 |
| NCT03664050 | Ain Shams University | Induction of Ovulation | 2018-01-01 | PHASE3 |
| NCT02562118 | National University Hospital, Singapore|Eisai Co., Ltd. | Breast Cancer | 2015-10-02 | PHASE1|PHASE2 |
| NCT06650748 | Peking University | Breast Cancer|Early-stage Breast Cancer | 2025-05-01 | PHASE2 |
| NCT05469750 | Fujian Medical University Union Hospital | Advanced Breast Cancer | 2022-08-10 | PHASE2 |
| NCT07143682 | Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh | Polycystic Ovarian Syndrome (PCOS)|Infertility | 2023-01-08 | PHASE3 |
| NCT06998407 | Avenzo Therapeutics, Inc. | HR&addition;+HER2- Breast Cancer|HR&addition;, HER2-, Advanced Breast Cancer | 2025-08-20 | PHASE1|PHASE2 |
| NCT00687648 | National Cancer Centre, Singapore | Breast Cancer | 2008-05 | PHASE2 |
| NCT04557449 | Pfizer | Liposarcoma|Prostate Cancer|Breast Neoplasms|Adenocarcinoma of Lung | 2020-09-23 | PHASE2 |
| NCT03056755 | Novartis Pharmaceuticals | Breast Cancer | 2017-08-29 | PHASE2 |
| NCT06047184 | BeBetter Med Inc|Hunan Cancer Hospital|Xiangya Hospital of Central South University | Advanced Breast Cancer | 2019-07-15 | PHASE1 |
| NCT02769104 | Zhejiang Cancer Hospital | Neoadjuvant Therapy | 2016-05 | PHASE3 |
| NCT01068704 | Bristol-Myers Squibb | Breast Cancer | 2010-06 | PHASE2 |
| NCT01208441 | National Cancer Institute (NCI) | Estrogen Receptor-positive Breast Cancer|HER2-negative Breast Cancer|Progesterone Receptor-positive Breast Cancer|Stage II Breast Cancer|Stage IIIA Breast Cancer | 2010-11 | PHASE1 |
| NCT01248494 | Vanderbilt-Ingram Cancer Center | Metastatic Breast Cancer | 2010-11 | PHASE1 |
| NCT02305693 | Cairo University | Infertility | 2014-11 | PHASE3 |
| NCT04364581 | Mansoura University | Myoma;Uterus | 2020-05-01 | PHASE4 |
| NCT05582499 | Fudan University | Breast Neoplasm|Breast Cancer|Breast Tumors|Triple-Negative Breast Cancer (TNBC)|HER2-positive Breast Cancer|HER2-negative Breast Cancer|Hormone Receptor Positive Tumor|Hormone Receptor Negative Tumor|Early-stage Breast Cancer|Locally Advanced Breast Cancer | 2022-11-01 | PHASE2 |
| NCT06390904 | Xiaojun Chen | Atypical Endometrial Hyperplasia|Progesterone Resistance|Obesity | 2022-07-13 | PHASE2|PHASE3 |
| NCT00263198 | Washington University School of Medicine|Novartis | Breast Neoplasms | 2006-03 | PHASE2 |
| NCT04486911 | Shengjing Hospital | Breast Cancer | 2020-07-27 | PHASE2 |
| NCT05106712 | Umm Al-Qura University | Female Infertility|Polycystic Ovary Syndrome|Pathologic Processes|Vitamin D Deficiency|IVF|Vitamin D Supplement | 2021-11-01 | NA |
| NCT04289805 | Erasme University Hospital|University Hospital, Lille | Breast Neoplasm Malignant Female | 2019-02-25 | PHASE4 |
| NCT05157672 | Washington State University|National Center for Complementary and Integrative Health (NCCIH)|Office of Dietary Supplements (ODS) | Interaction Drug Food | 2021-12-14 | EARLY_PHASE1 |
| NCT06405243 | Beni-Suef University | Polycystic Ovary Syndrome | 2024-06-30 | PHASE3 |
| NCT04294225 | Mayo Clinic|National Cancer Institute (NCI) | Anatomic Stage I Breast Cancer AJCC v8|Anatomic Stage IA Breast Cancer AJCC v8|Anatomic Stage IB Breast Cancer AJCC v8|Anatomic Stage II Breast Cancer AJCC v8|Anatomic Stage IIA Breast Cancer AJCC v8|Anatomic Stage IIB Breast Cancer AJCC v8|Anatomic Stage III Breast Cancer AJCC v8|Anatomic Stage IIIA Breast Cancer AJCC v8|Anatomic Stage IIIB Breast Cancer AJCC v8|Anatomic Stage IIIC Breast Cancer AJCC v8|Early-Stage Breast Carcinoma|Invasive Breast Carcinoma|Prognostic Stage I Breast Cancer AJCC v8|Prognostic Stage IA Breast Cancer AJCC v8|Prognostic Stage IB Breast Cancer AJCC v8|Prognostic Stage II Breast Cancer AJCC v8|Prognostic Stage IIA Breast Cancer AJCC v8|Prognostic Stage IIB Breast Cancer AJCC v8|Prognostic Stage III Breast Cancer AJCC v8|Prognostic Stage IIIA Breast Cancer AJCC v8|Prognostic Stage IIIB Breast Cancer AJCC v8|Prognostic Stage IIIC Breast Cancer AJCC v8 | 2020-04-28 | PHASE2 |
| NCT07340658 | Rovi Pharmaceuticals Laboratories | Advanced, Metastatic Breast Cancer | 2026-08 | PHASE3 |
| NCT00351416 | Massachusetts General Hospital|National Institutes of Health (NIH) | Healthy Volunteers | 2004-01-21 | PHASE1|PHASE2 |
| NCT07174336 | Eli Lilly and Company|Pfizer | Breast Neoplasms|Neoplasm Metastasis | 2025-12-22 | PHASE3 |
| NCT05437471 | Universiti Kebangsaan Malaysia Medical Centre | Miscarriage, Recurrent | 2020-01-01 | NA |
| NCT05207644 | Gynuity Health Projects | Pregnancy | 2021-12-09 | PHASE2 |
| NCT00194779 | University of Washington|National Cancer Institute (NCI) | Estrogen Receptor-negative Breast Cancer|Estrogen Receptor-positive Breast Cancer|HER2-positive Breast Cancer|Progesterone Receptor-negative Breast Cancer|Progesterone Receptor-positive Breast Cancer|Stage IA Breast Cancer|Stage IB Breast Cancer|Stage II Breast Cancer|Stage IIIA Breast Cancer | 2003-10 | PHASE2 |
| NCT06979596 | Merck Sharp & Dohme LLC | Malignant Neoplasm | 2025-08-11 | PHASE2 |
| NCT04193930 | Assiut University | ART | 2021-01-01 | NA |
| NCT00956267 | Mansoura University | Polycystic Ovary Syndrome | 2006-08 | NA |
| NCT06507332 | Egymedicalpedia|Ain Shams University | Polycystic Ovary Syndrome | 2024-03-01 | NA |
| NCT04524026 | Nicholas Macklon|Gedeon Richter Ltd.|Igenomix | IVF | 2018-09-18 | PHASE2 |
| NCT07159880 | GABRIEL MONTEIRO PINHEIRO | PCOS (Polycystic Ovary Syndrome)|Infertility|Anovulation | 2025-09-01 | NA |
| NCT01035099 | Weill Medical College of Cornell University | Breast Cancer|Infertility | 2009-11 | PHASE4 |
| NCT05766410 | National Taiwan University Hospital | Breast Cancer|Hormone Receptor-positive Breast Cancer|Hormone Therapy | 2022-09-16 | PHASE2 |
| NCT04308343 | Assiut University | Ectopic Pregnancy | 2020-03-30 | NA |
| NCT00823004 | Yazd Research & Clinical Center for Infertility | Ovarian Stimulation | 2008-06 | PHASE1|PHASE2 |
| NCT03966898 | Jiangsu HengRui Medicine Co., Ltd. | Advanced Breast Cancer | 2019-07-19 | PHASE3 |
| NCT00498901 | University of Washington|National Cancer Institute (NCI) | Breast Cancer | 2007-02 | PHASE2 |
| NCT00499681 | Vanderbilt-Ingram Cancer Center|National Cancer Institute (NCI) | Breast Cancer | 2007-07 | PHASE2 |
| NCT02661932 | Erasme University Hospital | Breast Neoplasms|Fertility | 2012-11 | PHASE4 |
| NCT07401381 | Rovi Pharmaceuticals Laboratories | Hormone Receptor Positive Early Breast Cancer | 2026-03 | PHASE1 |
| NCT04563507 | Weill Medical College of Cornell University | Breast Cancer | 2020-11-12 | PHASE2 |
| NCT04577001 | Mayo Clinic|University of California, San Francisco | Hepatopulmonary Syndrome | 2021-02-18 | PHASE2 |
| NCT02865681 | New Hope Fertility Center | Infertility | 2016-07-01 | NA |
| NCT00708214 | Boehringer Ingelheim | Breast Neoplasms | 2007-01 | PHASE2 |
| NCT02802748 | SOLTI Breast Cancer Research Group|Pierre Fabre Laboratories | Breast Cancer | 2016-07 | EARLY_PHASE1 |
| NCT02946684 | Sven O. Skouby|Rigshospitalet, Denmark|Hvidovre University Hospital|Holbaek Sygehus|Region Capital Denmark|Copenhagen University Hospital, Denmark|Zealand University Hospital | Infertility | 2017-02-01 | PHASE2|PHASE3 |
| NCT02670304 | First Affiliated Hospital, Sun Yat-Sen University | Ovarian Hyperstimulation Syndrome | 2012-01 | PHASE4 |
| NCT02400567 | UNICANCER|Pfizer|NanoString Technologies, Inc. | Neoadjuvant Operable Breast Cancer | 2015-01 | PHASE2 |
| NCT01612871 | Institut Claudius Regaud | Breast Cancer | 2012-06-27 | PHASE4 |
| NCT05601700 | Ente Ospedaliero Ospedali Galliera|Istituto Di Ricerche Farmacologiche Mario Negri|Humanitas Hospital, Italy | Carcinoma, Ovarian Epithelial|Low Grade Serous Adenocarcinoma of Ovary | 2022-09-22 | PHASE3 |
| NCT04964934 | AstraZeneca | ER-Positive HER2-Negative Breast Cancer | 2021-06-30 | PHASE3 |
| NCT03554044 | University of California, San Francisco|Amgen | Anatomic Stage III Breast Cancer AJCC v8|Anatomic Stage IIIA Breast Cancer AJCC v8|Anatomic Stage IIIB Breast Cancer AJCC v8|Anatomic Stage IIIC Breast Cancer AJCC v8|Anatomic Stage IV Breast Cancer AJCC v8|Estrogen Receptor Positive|HER2+Neu Negative|Invasive Breast Carcinoma|Prognostic Stage III Breast Cancer AJCC v8|Prognostic Stage IIIA Breast Cancer AJCC v8|Prognostic Stage IIIB Breast Cancer AJCC v8|Prognostic Stage IIIC Breast Cancer AJCC v8|Prognostic Stage IV Breast Cancer AJCC v8|Recurrent Breast Carcinoma | 2020-02-05 | PHASE1 |
| NCT02450175 | Sinai Hospital of Baltimore | Neoplasm | 2014-06 | NA |
| NCT02551367 | mostafa gomaa hamid halawa|Ain Shams Maternity Hospital | Anovulation|Polycystic Ovary Syndrome | 2015-10 | PHASE2 |
| NCT04407988 | Hunan Cancer Hospital|Jiangsu HengRui Medicine Co., Ltd. | Metastatic Breast Cancer | 2019-11-06 | PHASE2 |
| NCT06244745 | IVI Madrid | Luteinised Follicular Cyst | 2023-12-15 | PHASE3 |
| NCT03879577 | University of Chicago | Breast Cancer|Breast Cancer Female|HER2-positive Breast Cancer|Breast Cancer Stage II|Breast Cancer Stage III | 2019-11-25 | PHASE2 |
| NCT02095184 | University of Maryland, Baltimore | Breast Cancer | 2015-05-25 | NA |
| NCT00908531 | Danish Breast Cancer Cooperative Group|The Danish Medical Research Council|Danish Cancer Society|Novartis | Operable Breast Neoplasms | 2009-05 | PHASE3 |
| NCT01919229 | Novartis Pharmaceuticals | Early Breast Cancer | 2013-10 | PHASE2 |
| NCT04551495 | Jules Bordet Institute|Hoffmann-La Roche | Invasive Lobular Breast Carcinoma|ER&addition; Breast Cancer|HER2-negative Breast Cancer | 2021-01-14 | PHASE2 |
| NCT05649956 | GOG Foundation | Uterine Leiomyosarcoma | 2024-07-17 | PHASE2 |
| NCT02297438 | Pfizer | Breast Neoplasms | 2015-03-23 | PHASE3 |
| NCT05467891 | Oana Danciu|Novartis Pharmaceuticals | Locoregional Recurrence|Hormone Receptor-positive Breast Cancer|HER2-negative Breast Cancer | 2022-09-13 | PHASE2 |
| NCT03962647 | Vanderbilt-Ingram Cancer Center | Estrogen Receptor-positive Breast Cancer | 2019-07-08 | EARLY_PHASE1 |
| NCT07178743 | Brigham and Women´s Hospital|Food and Drug Administration (FDA) | Advanced Breast Cancer | 2025-07-14 | |
| NCT00006174 | National Institute of Dental and Craniofacial Research (NIDCR) | McCune Albright Syndrome|Polyostotic Fibrous Dysplasia|Precocious Puberty | 2000-08-03 | PHASE1 |
| NCT04129216 | Johns Hopkins University|Agendia | Breast Cancer | 2019-02-20 | PHASE2 |
| NCT01758146 | Post Graduate Institute of Medical Education and Research, Chandigarh | Breast Cancer | 2012-01 | PHASE3 |
| NCT00044291 | Intarcia Therapeutics | Breast Neoplasms|Neoplasms, Hormone-dependent | 2002-06 | PHASE3 |
| NCT05203562 | Zagazig University | Gestational Trophoblastic Disease | 2020-06-01 | PHASE2|PHASE3 |
| NCT01872260 | Novartis Pharmaceuticals | Breast Cancer | 2013-10-22 | PHASE1|PHASE2 |
| NCT01296555 | Genentech, Inc. | Solid Cancers|Non-Hodgkin´s Lymphoma | 2011-03-16 | PHASE1 |
| NCT06143631 | University of California, San Francisco|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) | Leiomyoma, Uterine|Leiomyoma|Fibroid|Fibroid Uterus | 2024-07-24 | PHASE4 |
| NCT00107263 | Alliance for Clinical Trials in Oncology|National Cancer Institute (NCI) | Breast Cancer|Osteoporosis | 2005-01 | PHASE3 |
| NCT03179904 | Mayo Clinic | Advanced Breast Carcinoma|HER2-Positive Breast Carcinoma|Anatomic Stage III Breast Cancer AJCC v8|Anatomic Stage IV Breast Cancer AJCC v8|HER2-positive Breast Cancer | 2017-08-03 | PHASE2 |
| NCT04177693 | Yale University|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)|University of Illinois at Chicago|Johns Hopkins University|University of Chicago | Uterine Fibroids | 2020-11-24 | PHASE1 |
| NCT05702957 | Services Institute of Medical Sciences, Pakistan | Polycystic Ovary Syndrome|Infertility | 2016-09 | PHASE2|PHASE3 |
| NCT02491983 | MedSIR | Metastatic Breast Cancer | 2015-08 | PHASE2 |
| NCT04606446 | Pfizer | Locally Advanced or Metastatic ER&addition; HER2- Breast Cancer|Locally Advanced or Metastatic Castration-resistant Prostate Cancer|Locally Advanced or Metastatic Non-small Cell Lung Cancer | 2020-11-16 | PHASE2 |
| NCT01275859 | Asan Medical Center | Breast Cancer | 2010-09 | PHASE2 |
| NCT01372982 | Dr. Reddy´s Laboratories Limited | Healthy | 2008-04 | PHASE1 |
| NCT00247663 | Novartis Pharmaceuticals|Chugai Pharmaceutical | Postmenopausal Women With Advanced Breast Cancer | 1999-12 | PHASE2 |
| NCT05765305 | Cairo University | Polycystic Ovary Syndrome | 2018-09-01 | |
| NCT03709082 | University of Kansas Medical Center|Pfizer | HER2-positive Breast Cancer|Breast Cancer Metastatic | 2018-10-15 | PHASE1|PHASE2 |
| NCT00634634 | Rutgers, The State University of New Jersey|Rutgers Cancer Institute of New Jersey|National Cancer Institute (NCI)|Bayer|Novartis Pharmaceuticals | Metastatic Breast Cancer | 2008-08-11 | PHASE1|PHASE2 |
| NCT02293668 | Istanbul University | Infertility | 2014-11 | NA |
| NCT03822468 | Novartis Pharmaceuticals | Breast Cancer | 2019-06-11 | PHASE2 |
| NCT06223698 | Region ?rebro County|Mid-Sweden Regional Cancer Centre|Uppsala University Hospital | Breast Cancer | 2025-05-02 | PHASE3 |
| NCT00770354 | Antisoma Research | Breast Carcinoma | 2008-09 | PHASE2 |
| NCT02806050 | University Medical Center Groningen | Breast Cancer | 2016-09-16 | PHASE2 |
| NCT05839561 | Jagiellonian University | Tubal Pregnancy Unruptured | 2020-12-01 | NA |
| NCT03901170 | National Taiwan University Hospital | Investigative Techniques|Reproductive Techniques|Reproductive Techniques, Assisted | 2019-04-25 | PHASE4 |
| NCT03874325 | H. Lee Moffitt Cancer Center and Research Institute|AstraZeneca | Breast Cancer|Hormone Receptor Positive Tumor | 2019-04-26 | PHASE2 |
| NCT01577017 | Nik Hazlina | Polycystic Ovarian Syndrome | 2008-05 | PHASE3 |
| NCT00171340 | Novartis Pharmaceuticals | Bone Loss|Breast Cancer | 2003-05 | PHASE3 |
| NCT00673335 | UNICANCER | brca1 Mutation Carrier|brca2 Mutation Carrier|Breast Cancer|Hereditary Breast+Ovarian Cancer (brca1, brca2) | 2008-05 | PHASE3 |
| NCT04069117 | Mansoura University Hospital | Polycystic Ovarian Syndrome | 2019-08-01 | PHASE4 |
| NCT04102618 | Oncolytics Biotech|SOLTI Breast Cancer Research Group | Breast Cancer | 2019-03-29 | EARLY_PHASE1 |
| NCT05205837 | Rigshospitalet, Denmark | Hypogonadism|Hypogonadism, Male|Hypogonadotropic Hypogonadism | 2021-11-24 | PHASE4 |
| NCT06367712 | Egymedicalpedia | PCOS (Polycystic Ovary Syndrome) of Bilateral Ovaries | 2022-11-10 | PHASE1 |
| NCT06985186 | University of Palermo | Adenomyosis of Uterus|Infertility Assisted Reproductive Technology | 2025-06 | PHASE4 |
| NCT04852081 | Blokhin´s Russian Cancer Research Center | Breast Cancer Stage IV | 2021-01-01 | |
| NCT04361175 | Assiut University | Infertility | 2021-03 | EARLY_PHASE1 |
| NCT00073528 | Novartis Pharmaceuticals | Breast Neoplasms | 2003-12-09 | PHASE3 |
| NCT02939898 | Sven O. Skouby|Rigshospitalet, Denmark|Region Capital Denmark|Copenhagen University Hospital, Denmark | Infertility | 2016-08 | PHASE2|PHASE3 |
| NCT03675893 | Dana-Farber Cancer Institute|Eli Lilly and Company|Effector Therapeutics|Celcuity Inc | Endometrial Cancer|Ovarian Cancer | 2018-12-24 | PHASE2 |
| NCT02730429 | Nordic Society of Gynaecological Oncology - Clinical Trials Unit|European Network of Gynaecological Oncological Trial Groups (ENGOT)|Gynecologic Cancer Intergroup (GCIG)|North Eastern German Society of Gynaecological Oncology|Multicenter Italian Trials in Ovarian cancer and gynecologic malignancies (MITO)|Grupo Espa?ol de Investigación en Cáncer de Ovario | Endometrial Cancer | 2017-02-15 | PHASE2 |
| NCT00403182 | Technical University of Munich | Breast Cancer | 2006-05 | PHASE3 |
| NCT00688909 | Novartis Pharmaceuticals | Breast Cancer | 2008-03 | PHASE4 |
| NCT06041204 | Muhamed Ahmed Abdelmoaty Muhamed Alhagrasy | PCOS (Polycystic Ovary Syndrome) of Bilateral Ovaries|Subclinical Hypothyroidism|Female Infertility | 2021-05-06 | NA |
| NCT04137640 | Shengjing Hospital | Breast Cancer | 2021-07-19 | PHASE4 |
| NCT02907918 | Washington University School of Medicine|Pfizer|Rising Tide Foundation | Breast Cancer|Cancer of Breast|Breast Carcinoma | 2017-06-30 | PHASE2 |
| NCT01194440 | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Ductal Carcinoma in Situ|Estrogen Receptor-positive Breast Cancer|Progesterone Receptor-positive Breast Cancer|Stage I Breast Cancer|Stage II Breast Cancer|Stage IIIA Breast Cancer|Stage IIIB Breast Cancer|Stage IIIC Breast Cancer | 2011-02 | PHASE2 |
| NCT01072318 | Korean Breast Cancer Study Group | Breast Cancer | 2010-01 | PHASE4 |
| NCT06504082 | Yuzuncu Yil University | Ectopic Pregnancy | 2021-09-20 | NA |
| NCT05472792 | UNC Lineberger Comprehensive Cancer Center | Breast Cancer|Quality of Life | 2022-05-17 | PHASE2 |
| NCT03006172 | Genentech, Inc. | Breast Cancer|Solid Tumor | 2016-12-13 | PHASE1 |
| NCT04130152 | SOLTI Breast Cancer Research Group|Pfizer | Breast Cancer | 2019-11-21 | EARLY_PHASE1 |
| NCT07183787 | Sidra Salman | Endometriosis | 2019-04-10 | PHASE2 |
| NCT00001521 | Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) | Congenital Adrenal Hyperplasia (CAH) | 1995-06-08 | PHASE3 |
| NCT05900206 | Karolinska University Hospital | Breast Cancer | 2023-10-26 | PHASE2 |
| NCT02158689 | Ercan Bastu | Poor Responders | 2014-06 | NA |
| NCT00107016 | Novartis Pharmaceuticals | Breast Neoplasm | 2005-03 | PHASE2 |
| NCT01896050 | University of Michigan Rogel Cancer Center | Breast Cancer|Arthralgia|Obesity | 2009-09 | |
| NCT02142868 | Pfizer | Advanced Breast Cancer (Female) | | |
| NCT04619914 | Laylay Mohammed Khalleefah Alhibshi | Endometrial Thickness|Pregnancy Rate | 2019-03-01 | NA |
| NCT05150652 | Irada Ibrahim-zada | Breast Cancer|HER2-negative Breast Cancer|Node-negative Breast Cancer|Breast Carcinoma | 2022-02-18 | PHASE2 |
| NCT05075863 | Nishtar Medical University | Polycystic Ovary Syndrome | 2021-01-01 | NA |
| NCT04293393 | Spanish Breast Cancer Research Group|Eli Lilly and Company | Early Breast Cancer | 2020-10-02 | PHASE2 |
| NCT01013506 | Vanderbilt-Ingram Cancer Center|National Cancer Institute (NCI) | Breast Cancer | 2009-08 | PHASE2 |
| NCT06492616 | Stemline Therapeutics, Inc. | Breast Cancer | 2024-09-27 | PHASE3 |
| NCT00332852 | Novartis Pharmaceuticals | Breast Cancer | 2006-03 | PHASE3 |
| NCT04215835 | Cairo University | Missed Abortion | 2020-01-05 | PHASE4 |
| NCT00565240 | University of Saskatchewan|Canadian Institutes of Health Research (CIHR) | Ovarian Follicle | 2007-11 | NA |
| NCT05198050 | Cairo University | Anembryonic Pregnancy | 2022-04-03 | NA |
| NCT02097680 | University Hospital, Ghent | Obesity | 2013-12 | PHASE4 |
| NCT02619162 | Centro Nacional de Investigaciones Oncologicas CARLOS III|Dr. Miguel Angel Quintela Fandi?o (CNIO)|Dr, Ramón Colomer i Bosch|FUNDACIóN CRIS (Marta Cardona) as promotor | Breast Cancer | 2015-07 | PHASE1 |
| NCT00280930 | Dana-Farber Cancer Institute|Beth Israel Deaconess Medical Center|Brigham and Women´s Hospital|Massachusetts General Hospital | Post-Menopausal|Breast Cancer | 2005-10 | PHASE2 |
| NCT03774472 | M.D. Anderson Cancer Center | Anatomic Stage I Breast Cancer AJCC v8|Anatomic Stage IA Breast Cancer AJCC v8|Anatomic Stage IB Breast Cancer AJCC v8|Anatomic Stage II Breast Cancer AJCC v8|Anatomic Stage IIA Breast Cancer AJCC v8|Anatomic Stage IIB Breast Cancer AJCC v8|Anatomic Stage III Breast Cancer AJCC v8|Anatomic Stage IIIA Breast Cancer AJCC v8|Anatomic Stage IIIB Breast Cancer AJCC v8|Anatomic Stage IIIC Breast Cancer AJCC v8|Anatomic Stage IV Breast Cancer AJCC v8|Prognostic Stage I Breast Cancer AJCC v8|Prognostic Stage IA Breast Cancer AJCC v8|Prognostic Stage IB Breast Cancer AJCC v8|Prognostic Stage IIA Breast Cancer AJCC v8|Prognostic Stage IIB Breast Cancer AJCC v8|Prognostic Stage III Breast Cancer AJCC v8|Prognostic Stage IIIA Breast Cancer AJCC v8|Prognostic Stage IIIB Breast Cancer AJCC v8|Prognostic Stage IIIC Breast Cancer AJCC v8|Prognostic Stage IV Breast Cancer AJCC v8 | 2018-08-20 | PHASE1|PHASE2 |
| NCT04169451 | Peking University Third Hospital|The First Affiliated Hospital of Anhui Medical University|The Second Hospital of Hebei Medical University|Tianjin Central Hospitalof Gynecology Obstetrics|Yunnan1stpeople´s hospital | Intrauterine Insemination|Unexplained Infertility | 2022-09-29 | NA |
| NCT06075953 | QuantumLeap Healthcare Collaborative | Ductal Carcinoma in Situ | 2024-02-17 | PHASE2 |
| NCT00545077 | Spanish Breast Cancer Research Group|Hoffmann-La Roche|GBG Forschungs GmbH | Breast Cancer | 2007-11-06 | PHASE3 |
| NCT05774951 | AstraZeneca | Breast Cancer, Early Breast Cancer | 2023-03-31 | PHASE3 |
| NCT07448272 | Mst.Sumyara Khatun|Bangladesh Medical University | PCOS (Polycystic Ovary Syndrome) | 2025-04-01 | NA |
| NCT04421547 | Fondazione Policlinico Universitario Agostino Gemelli IRCCS | Epithelial Ovarian Cancer | 2020-06-22 | PHASE3 |
| NCT03673124 | Gynecologic Oncology Group|Novartis | Low Grade Serous Carcinoma | 2019-05-20 | PHASE2 |
| NCT04300790 | MedSIR|Novartis | Breast Cancer | 2020-10-23 | PHASE2 |
| NCT00997373 | University of California, Davis | Endometrial Carcinoma | 2009-10 | NA |
| NCT04134598 | Azienda Ospedaliero-Universitaria Careggi|University of Florence | Breast Cancer | 2021-02-08 | PHASE3 |
| NCT00754845 | Canadian Cancer Trials Group|Eastern Cooperative Oncology Group|North Central Cancer Treatment Group|SWOG Cancer Research Network|Alliance for Clinical Trials in Oncology | Breast Cancer | 2004-11-23 | PHASE3 |
| NCT00532272 | National Cancer Center, Korea | Metastatic Breast Cancer | 2005-10 | PHASE2 |
| NCT01615211 | Kristina Gemzell Danielsson|Karolinska Institutet|The University of Hong Kong | Medical Abortion, Complete or Unspecified, Without Complication | 2012-05 | PHASE2 |
| NCT05872204 | Universitaire Ziekenhuizen KU Leuven|Kom Op Tegen Kanker|Eli Lilly and Company|European Network of Gynaecological Oncological Trial Groups (ENGOT) | Low Grade Serous Ovarian Carcinoma|Adult Type Granulosa Cell Tumor | 2023-11-30 | PHASE2 |
| NCT07085767 | Olema Pharmaceuticals, Inc.|Novartis Pharmaceuticals | Breast Cancer|Locally Advanced Breast Cancer|Metastatic Breast Cancer|ER Positive Breast Cancer|HER2 Negative Breast Carcinoma | 2025-11-03 | PHASE3 |
| NCT01116167 | Heilongjiang University of Chinese Medicine|Ministry of Science and Technology of the People?s Republic of China | Polycystic Ovary Syndrome | 2009-10 | NA |
| NCT01908556 | Institut fuer Frauengesundheit|Novartis|ClinSol | is to Identify Biomarkers That Could Predict the Efficacy of an Adjuvant Letrozol Treatment in Postmenopausal Breast Cancer Patients. | 2009-02 | PHASE4 |
| NCT03772353 | Fudan University|Jiangsu HengRui Medicine Co., Ltd. | Breast Cancer | 2019-05-12 | PHASE1|PHASE2 |
| NCT01720602 | University of Washington|National Cancer Institute (NCI) | Male Breast Cancer|Recurrent Breast Cancer|Stage IV Breast Cancer | 2012-11 | NA |
| NCT00290745 | University of California, San Francisco|Novartis | Breast Cancer | 2002-02-19 | PHASE1|PHASE2 |
| NCT00549822 | Massachusetts General Hospital|Dana-Farber Cancer Institute|Novartis | Breast Cancer | 2007-10 | PHASE2 |
| NCT03241472 | Assiut University | Infertility | 2016-02 | PHASE3 |
| NCT05705505 | Traws Pharma, Inc. | Endometrioid Endometrial Cancer | 2023-03-29 | PHASE1|PHASE2 |
| NCT01042379 | QuantumLeap Healthcare Collaborative | Breast Neoplasms|Breast Cancer|Breast Tumors|Angiosarcoma|TNBC - Triple-Negative Breast Cancer|HER2-positive Breast Cancer|HER2-negative Breast Cancer|Hormone Receptor Positive Tumor|Hormone Receptor Negative Tumor|Early-stage Breast Cancer|Locally Advanced Breast Cancer | 2010-03-01 | PHASE2 |
| NCT06605690 | Liu Shu | Breast Cancer | 2024-10-31 | NA |
| NCT02912988 | The University of Hong Kong|Peking University Third Hospital | Subfertility | 2018-03-01 | PHASE3 |
| NCT00436917 | Mayo Clinic|National Cancer Institute (NCI) | Breast Cancer|Osteoporosis | 2006-04 | NA |
| NCT00171808 | Novartis Pharmaceuticals | Endometrial Cancer | 2005-04 | PHASE2 |
| NCT02520063 | University of Alabama at Birmingham|Novartis Pharmaceuticals|Tracon Pharmaceuticals Inc. | Breast Cancer | 2015-02-01 | PHASE1|PHASE2 |
| NCT02154776 | Novartis Pharmaceuticals | Advanced or Metastatic Breast Cancer | 2014-06-27 | PHASE1 |
| NCT01475318 | The University of Hong Kong | Complete Abortion | 2011-10 | NA |
| NCT04095390 | Jinming Yu|Jiangsu HengRui Medicine Co., Ltd. | Metastatic Breast Cancer|HER2-positive Breast Cancer | 2019-09-30 | PHASE2 |
| NCT02128360 | Sheba Medical Center | Infertility | 2015-03 | NA |
| NCT00903162 | Dana-Farber Cancer Institute|Beth Israel Deaconess Medical Center|Novartis | Breast Cancer | 2009-05 | PHASE2 |
| NCT03285802 | Greater Baltimore Medical Center | Uterine Cancer | 2017-09-07 | PHASE2|PHASE3 |
| NCT00461773 | Yale University|Novartis|Genentech, Inc. | Hormone-Sensitive Breast Cancer|Breast Cancer | 2007-03 | PHASE2 |
| NCT07379502 | CMH Kharian Medical College | PCOS (Polycystic Ovary Syndrome) | 2026-03-05 | NA |
| NCT01044862 | Yale University|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)|Penn State University|University of Colorado, Denver|University of Michigan|University of Pennsylvania|University of Texas|University of Vermont|Wayne State University | Pregnancy|Unexplained Infertility | 2010-06 | PHASE3 |
| NCT02765373 | Chinese Academy of Medical Sciences | Breast Cancer | 2015-01 | |
| NCT02101788 | National Cancer Institute (NCI)|NRG Oncology | Borderline Ovarian Serous Tumor|Micropapillary Serous Carcinoma|Ovarian Serous Adenocarcinoma|Primary Peritoneal Serous Adenocarcinoma|Recurrent Ovarian Low Grade Serous Adenocarcinoma|Recurrent Primary Peritoneal Serous Adenocarcinoma | 2014-04-11 | PHASE2|PHASE3 |
| NCT00553410 | ETOP IBCSG Partners Foundation|Breast International Group | Breast Cancer | 2007-08 | PHASE3 |
| NCT04478266 | Sanofi | Breast Cancer | 2020-10-14 | PHASE3 |
| NCT01272037 | National Cancer Institute (NCI) | Breast Ductal Carcinoma In Situ|Invasive Breast Carcinoma|Multicentric Breast Carcinoma|Multifocal Breast Carcinoma|Synchronous Bilateral Breast Carcinoma | 2011-02-28 | PHASE3 |
| NCT01199367 | Kyowa Kirin Co., Ltd.|Kyowa Hakko Kirin Pharma, Inc. | Breast Cancer | 2010-12 | PHASE1 |
| NCT00719966 | Mayo Clinic|National Cancer Institute (NCI) | Breast Cancer | 2008-09-18 | |
| NCT01129622 | Mount Sinai Hospital, Canada | Breast Cancer | 2008-10 | PHASE2 |
| NCT04571437 | Cairo University | Breast Cancer|Estrogen Receptor-positive Breast Cancer|Metastatic Breast Cancer | 2020-03-01 | PHASE2 |
| NCT01797523 | M.D. Anderson Cancer Center|Novartis|National Cancer Institute (NCI) | Endometrial Cancer | 2013-10-07 | PHASE2 |
| NCT07285382 | wanghaibo | HR Positive HER2 Negative Advanced Breast Cancer | 2025-06-25 | PHASE2 |
| NCT02753686 | Novartis Pharmaceuticals | HR&addition; HER2- Men, Pre+Postmenopausal Advanced Breast Cancer | 2016-03-15 | |
| NCT00894608 | Yunyang Medical College | Polycystic Ovarian Syndrome | 2008-01 | NA |
| NCT05839574 | Jagiellonian University | Cesarean Scar Pregnancy | 2021-01-01 | NA |
| NCT07349069 | Shandong Suncadia Medicine Co., Ltd. | Breast Cancer | 2026-03-04 | PHASE3 |
| NCT06341283 | The Affiliated Hospital of Qingdao University | Breast Cancer|Neoplasms|Breast Diseases | 2024-06-01 | |
| NCT02333370 | Novartis Pharmaceuticals | Hormone Receptor Positive, HER2-negative, Advanced Breast Cancer | 2015-02-04 | PHASE1 |
| NCT06654570 | Helsinki University Central Hospital | Breast Cancer | 2020-04-08 | PHASE2 |
| NCT06405178 | Beni-Suef University | Polycystic Ovary | 2024-09-30 | PHASE3 |
| NCT04159649 | Mansoura University|Zagazig University | EMBRYO IMPLANTATION | 2019-12-01 | PHASE4 |
| NCT04220476 | Weill Medical College of Cornell University | Breast Cancer | 2020-03-04 | PHASE2 |
| NCT06120283 | BeOne Medicines | Advanced Solid Tumor|Advanced Breast Cancer|Metastatic Breast Cancer|Hormone-receptor-positive Breast Cancer|Hormone Receptor Positive Breast Carcinoma|Hormone Receptor Positive Malignant Neoplasm of Breast|HER2-negative Breast Cancer|Hormone Receptor Positive HER-2 Negative Breast Cancer|Non-small Cell Lung Cancer | 2023-12-01 | PHASE1 |
| NCT07255911 | Mst.Sumyara Khatun|Bangladesh Medical University | PCOS | 2025-02-07 | NA |
| NCT02389088 | University of California, San Diego | Polycystic Ovary Syndrome | 2006-04 | NA |
| NCT00960960 | Genentech, Inc. | Breast Cancer | 2009-08 | PHASE1 |
| NCT03455426 | Peking University Third Hospital | Infertility|Intrauterine Insemination | 2018-03-15 | NA |
| NCT05067309 | Ahmed Elsayed Aref | Termination of Early Pregnancy in Scarred Uterus | 2021-10-01 | |
| NCT05909397 | Pfizer|Arvinas Estrogen Receptor, Inc. | Breast Cancer | 2023-08-09 | PHASE3 |
| NCT03009838 | Assiut University | Infertility | 2017-01-02 | PHASE3 |
| NCT00880009 | Pfizer | Breast Cancer | 2009-07-30 | PHASE2 |
| NCT03440359 | Eastern Virginia Medical School|Watson Pharmaceuticals | Polycystic Ovary Syndrome | 2012-07-06 | PHASE2|PHASE3 |
| NCT06366347 | Dana-Farber Cancer Institute|Eli Lilly and Company | Endometrial Cancer|Recurrent Endometrial Cancer|TP53 | 2024-09-25 | PHASE2 |
| NCT03936270 | Latin American Cooperative Oncology Group|Pfizer | Ovarian Cancer | 2020-03-05 | PHASE2 |
| NCT00062751 | Wyeth is now a wholly owned subsidiary of Pfizer|Pfizer | Breast Neoplasms | 2002-12 | PHASE2 |
| NCT02686151 | The Affiliated Hospital of Inner Mongolia Medical University | Ovarian Hyperstimulation Syndrome | 2023-12 | PHASE3 |
| NCT03135301 | Assiut University | Infertility, Female | 2017-06-20 | PHASE3 |
| NCT00090857 | Dana-Farber Cancer Institute|National Cancer Institute (NCI)|Jonsson Comprehensive Cancer Center | Breast Cancer | 2002-02 | PHASE2 |
| NCT02763566 | Eli Lilly and Company | Breast Cancer | 2016-12-05 | PHASE3 |
| NCT00422903 | GlaxoSmithKline | Neoplasms, Breast | 2007-04 | PHASE2 |
| NCT05979220 | Shuangyue Liu | Breast Cancer | 2023-12-01 | PHASE2 |
| NCT06465368 | Pfizer | Breast Cancer | 2024-07-11 | PHASE2 |
| NCT02657928 | Mayo Clinic|National Cancer Institute (NCI) | Estrogen Receptor Positive|Postmenopausal|Recurrent Fallopian Tube Carcinoma|Recurrent Ovarian Carcinoma|Recurrent Primary Peritoneal Carcinoma|Recurrent Uterine Corpus Carcinoma | 2016-07-08 | PHASE2 |
| NCT05226871 | Pfizer | Breast Cancer|Head and Neck Cancer | 2022-07-07 | PHASE2 |
| NCT00332709 | Novartis | Osteoporosis|Postmenopausal | 2006-01 | PHASE3 |
| NCT04942899 | Assiut University | Metastasis Breast | 2023-08-30 | PHASE2 |
| NCT05569811 | SOLTI Breast Cancer Research Group|Daiichi Sankyo | Breast Cancer | 2022-11-25 | PHASE2 |
| NCT06525675 | MedSIR|Pfizer | Metastatic Breast Cancer|Advanced Breast Cancer|Luminal Breast Cancer|HER2-negative Breast Cancer|ER-positive Breast Cancer | 2022-07-18 | |
| NCT03507465 | Guangdong Provincial People´s Hospital | Breast Cancer | 2017-11-29 | PHASE2|PHASE3 |
| NCT07168837 | Al-Azhar University | PCOS (Polycystic Ovary Syndrome) | 2023-01-10 | NA |
| NCT05867251 | Avenzo Therapeutics, Inc. | Advanced Solid Tumor|HR&addition;+HER2- Breast Cancer|HR&addition;, HER2-, Advanced Breast Cancer|CCNE1 Amplification|Epithelial Ovarian Cancer|Primary Peritoneal Cancer|Fallopian Tube Cancer|Endometrial Cancer|TNBC - Triple-Negative Breast Cancer | 2023-08-30 | PHASE1|PHASE2 |
| NCT04614194 | University of Texas Southwestern Medical Center|Eli Lilly and Company|Cancer Prevention Research Institute of Texas | Breast Cancer | 2021-04-15 | PHASE2 |
| NCT02313051 | Chinese Academy of Medical Sciences|Novartis Pharmaceuticals | Metastatic Breast Cancer | 2014-12 | PHASE2 |
| NCT00333086 | Novartis Pharmaceuticals|Canadian Cancer Trials Group | Recurrent and Metastatic Endometrial Cancer | 2000-01 | PHASE2 |
| NCT05487092 | The University of Hong Kong|Pamela Youde Nethersole Eastern Hospital|The Queen Elizabeth Hospital|Kwong Wah Hospital|Princess Margaret Hospital, Canada | Endometriotic Cyst of Ovary | 2022-12-01 | NA |
| NCT02894398 | iOMEDICO AG|Pfizer | Breast Cancer|Hormone Receptor Positive Tumor|Human Epidermal Growth Factor 2 Negative Carcinoma of Breast | 2016-09-06 | PHASE2 |
| NCT01368263 | Washington University School of Medicine|National Cancer Institute (NCI) | Estrogen Receptor-positive Breast Cancer|HER2-negative Breast Cancer|Stage II Breast Cancer|Stage IIIA Breast Cancer|Stage IIIB Breast Cancer|Stage IIIC Breast Cancer | 2011-09 | PHASE2 |
| NCT03481998 | Jiangsu HengRui Medicine Co., Ltd. | Advanced Breast Cancer | 2018-03-22 | PHASE1|PHASE2 |
| NCT02278120 | Novartis Pharmaceuticals | Advanced Metastatic Breast Cancer | 2014-11-20 | PHASE3 |
| NCT05247268 | Fudan University|Peking Union Medical College Hospital | Endometrial Neoplasm Malignant Stage I | 2022-03-11 | PHASE2 |
| NCT05227391 | Reproductive & Genetic Hospital of CITIC-Xiangya | PCOS | 2022-03-16 | NA |
| NCT00535418 | Novartis Pharmaceuticals | Breast Cancer | 2000-06 | PHASE2|PHASE3 |
| NCT01655225 | Eli Lilly and Company | Advanced Cancer|Metastatic Cancer|Non-Hodgkin´s Lymphoma|Metastatic Breast Cancer|Malignant Mesothelioma|Non-small Cell Lung Cancer | 2012-07-31 | PHASE1 |
| NCT01439711 | Alliance for Clinical Trials in Oncology|National Cancer Institute (NCI) | Breast Cancer | 2012-02 | PHASE2 |
| NCT04553133 | Pfizer | Small Cell Lung Cancer|Ovarian Cancer|Breast Cancer | 2020-09-16 | PHASE2 |
| NCT06813118 | HITEC-Institute of Medical Sciences | Polycystic Ovarian Syndrome | 2024-06-07 | PHASE1 |
| NCT03819010 | MedSIR|Pfizer | Breast Cancer | 2019-05-07 | PHASE2 |
| NCT04630210 | Universitaire Ziekenhuizen KU Leuven|KU Leuven | Breast Cancer | 2021-02 | EARLY_PHASE1 |
| NCT07014410 | Zhejiang Cancer Hospital | Breast Cancer | 2023-02-01 | PHASE2 |
| NCT00171704 | Novartis Pharmaceuticals|Danish Breast Cancer Cooperative Group|University of Sheffield | Hormone Sensitive Resected Primary Breast Cancer in Postmenopausal Women | 2005-04 | PHASE3 |
| NCT00238290 | Swiss Cancer Institute | Breast Cancer | 2005-05 | PHASE2 |
| NCT00138710 | Rijnstate Hospital | Hypogonadotrophic Hypogonadism|Obesity | 2005-08 | PHASE3 |
| NCT07394946 | Cancer Care Hospital & Research Centre Foundation, Lahore | Hormone Receptor-Positive, HER2-Negative, Node Positive Breast Cancer | 2026-06 | PHASE2 |
| NCT01457703 | University of Colorado, Denver|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) | Obesity | 2010-06 | NA |
| NCT06733727 | The University of Hong Kong|Queen Mary Hospital, Hong Kong|Pamela Youde Nethersole Eastern Hospital|Kwong Wah Hospital|Princess Margaret Hospital, Canada | Silent Miscarriage | 2024-12-06 | NA |
| NCT02739516 | Benha University | Unexplained Infertility | 2014-06 | PHASE3 |
| NCT04047758 | Shengjing Hospital | Breast Cancer | 2019-09-01 | PHASE3 |
| NCT01058252 | Galaxy Pharma (Pvt) Limited|Ova IVF & Reproductive Health Clinics, Karachi | Primary Infertility|Secondary Infertility|Low Responders|Mild to Moderate Male Factor Infertility | 2021-05 | |
| NCT00291135 | Carol Fabian, MD|Novartis | Breast Cancer | 2003-01 | PHASE2 |
| NCT00083993 | Wyeth is now a wholly owned subsidiary of Pfizer | Breast Neoplasms|Neoplasm Metastasis | 2004-05 | PHASE3 |
| NCT04852887 | NRG Oncology|National Cancer Institute (NCI) | Stage I Breast Cancer | 2021-06-23 | PHASE3 |
| NCT01353209 | University of Cincinnati|United States Department of Defense | Lymphangioleiomyomatosis | 2011-05 | PHASE2 |
| NCT01814397 | University of Michigan Rogel Cancer Center|Damon Runyon Cancer Research Foundation | Breast Cancer|Pain|Arthralgia | 2009-07 | |
| NCT06354439 | Hospital de Clinicas de Porto Alegre | Ectopic Pregnancy | 2024-03-27 | PHASE4 |
| NCT02775877 | Navy General Hospital, Beijing | Female Infertility Due to Nonimplantation of Ovum | 2016-05 | NA |
| NCT05286437 | National Cancer Centre, Singapore|MSD Pharma (Singapore) Pte Ltd | Hormone Receptor-Positive HER2-Negative Advanced Breast Cancer | 2023-02-15 | PHASE2 |
| NCT02457312 | The University of Hong Kong | Pregnancy | 2013-03 | PHASE2 |
| NCT02221999 | RenJi Hospital | Tubular Breast Cancer|Mucinous Breast Cancer|Invasive Ductal Breast Cancer|Inflammatory Breast Cancer | 2013-09 | PHASE2|PHASE3 |
| NCT06413771 | Uludag University | Infertility Unexplained | 2023-01-01 | NA |
| NCT02057133 | Eli Lilly and Company | Breast Neoplasms | 2014-03-10 | PHASE1 |
| NCT05940233 | Queen Savang Vadhana Memorial Hospital, Thailand | Medical; Abortion, Fetus | 2023-06-30 | NA |
| NCT00433589 | European Organisation for Research and Treatment of Cancer - EORTC|Agendia|Breast International Group|Roche Pharma AG|Novartis|Sanofi | Breast Cancer | 2007-02 | PHASE3 |
| NCT02947685 | Alliance Foundation Trials, LLC.|Pfizer|GBG Forschungs GmbH|Fondazione Michelangelo|PrECOG, LLC.|Breast Cancer Trials, Australia and New Zealand|Syneos Health|SOLTI Breast Cancer Research Group|UNICANCER | HER-2 Positive Breast Cancer|Estrogen Receptor Positive Breast Cancer | 2017-06-21 | PHASE3 |
| NCT03373708 | Zhiyong Yu | Breast Cancer|Chemotherapy|Endocrine Breast Diseases | 2017-12-20 | PHASE2|PHASE3 |
| NCT07101159 | Fujian Cancer Hospital | Early Breast Cancer|Adjuvant Therapy|Hormone Receptor Positive + HER2-negative Breast Cancer | 2025-09 | PHASE2 |
| NCT02137538 | Stanford University | Short Stature | 2009-11-18 | PHASE4 |
| NCT02778685 | City of Hope Medical Center|National Cancer Institute (NCI) | Metastatic Breast Carcinoma|Stage IV Breast Cancer AJCC v6 and v7 | 2016-09-30 | PHASE2 |
| NCT00265759 | Alliance for Clinical Trials in Oncology|National Cancer Institute (NCI)|Cancer and Leukemia Group B | Breast Cancer | 2006-01 | PHASE3 |
| NCT03219476 | Medical College of Wisconsin | Breast Cancer|Invasive Breast Cancer | 2017-02-05 | PHASE2 |
| NCT04590482 | Shereen Rady Abou El-fetouh | Missed Abortion | 2020-11-15 | PHASE4 |
| NCT06953882 | Yale University|Novartis|Breast Cancer Research Foundation | HER2 Negative Breast Cancer | 2025-07-09 | PHASE2 |
| NCT01375452 | Dr. Reddy´s Laboratories Limited | Healthy | 2008-03 | PHASE1 |
| NCT00329940 | Novartis Pharmaceuticals | Breast Cancer | 2005-11 | PHASE3 |
| NCT04059484 | Sanofi | Breast Cancer Metastatic | 2019-10-22 | PHASE2 |
| NCT05198141 | Zagazig University | Ectopic Pregnancy | 2020-12-15 | PHASE4 |
| NCT05454358 | Fudan University|Obstetrics & Gynecology Hospital of Fudan University | Endometrial Cancer | 2022-08-02 | PHASE2|PHASE3 |
| NCT02283658 | Mayo Clinic|National Cancer Institute (NCI) | Ovarian Endometrioid Adenocarcinoma|Ovarian Seromucinous Carcinoma|Ovarian Serous Cystadenocarcinoma|Ovarian Serous Surface Papillary Adenocarcinoma|Recurrent Fallopian Tube Carcinoma|Recurrent Ovarian Carcinoma|Recurrent Ovarian Germ Cell Tumor|Recurrent Primary Peritoneal Carcinoma|Undifferentiated Ovarian Carcinoma | 2014-11-14 | PHASE2 |
| NCT01679574 | Assiut University | Polycystic Ovary Syndrome | 2009-01 | NA |
| NCT02600923 | Pfizer | Advanced Breast Cancer Female | 2016-04-15 | PHASE3 |
| NCT03401320 | Rovi Pharmaceuticals Laboratories | Healthy | 2017-11-06 | PHASE1 |
| NCT01771458 | Institut Curie | Reccurent+Metastatic Solid Tumor Disease | 2012-10 | PHASE2 |
| NCT00651976 | Vanderbilt-Ingram Cancer Center|National Cancer Institute (NCI) | Breast Cancer | 2008-03 | EARLY_PHASE1 |
| NCT01205685 | Vanderbilt-Ingram Cancer Center | Hormone-sensitive Metastatic Breast Cancer | 2010-05 | PHASE2 |
| NCT03283384 | Borstkanker Onderzoek Groep|Novartis|Philips Healthcare | Breast Neoplasms | 2019-06-15 | PHASE2 |
| NCT00291109 | University of Kansas | Breast Cancer | 2003-01 | |
| NCT02684032 | Celcuity Inc | Breast Cancer | 2016-06-14 | PHASE1 |
| NCT02405156 | Ain Shams University | Miscarriage | 2015-03 | PHASE2|PHASE3 |
| NCT05800197 | Blokhin´s Russian Cancer Research Center | Breast Cancer|Neoadjuvant Endocrine Therapy | 2014-04-15 | |
| NCT07190443 | Japanese Foundation for Cancer Research|Japan Clinical Oncology Group | Breast Cancer|Locoregional Recurrence|Abemaciclib|Endocrine Therapy | 2025-02-07 | PHASE3 |
| NCT00416715 | University of Washington|National Cancer Institute (NCI) | Arthralgia|Musculoskeletal Complications|Pain|Recurrent Breast Cancer|Stage I Breast Cancer|Stage II Breast Cancer|Stage IIIA Breast Cancer|Stage IIIB Breast Cancer|Stage IIIC Breast Cancer | 2006-10 | PHASE2 |
| NCT00893061 | Centre Oscar Lambret | Breast Cancer | 2009-03-16 | PHASE3 |
| NCT06315205 | Rovi Pharmaceuticals Laboratories | Healthy | 2023-07-26 | PHASE1 |
| NCT03424005 | Hoffmann-La Roche|Gilead Sciences|Pfizer | Metastatic Breast Cancer | 2018-03-30 | PHASE1|PHASE2 |
| NCT00516542 | OHSU Knight Cancer Institute|National Cancer Institute (NCI) | Breast Cancer | 2007-06 | PHASE1 |
| NCT04194658 | Cairo University | Medical; Abortion, Fetus | 2020-01 | PHASE2 |
| NCT00004251 | NCIC Clinical Trials Group | Endometrial Cancer | 2000-01-19 | PHASE2 |
| NCT03355157 | GBG Forschungs GmbH|Pfizer|AMS Advanced Medical Services GmbH | Metastatic Breast Cancer | 2018-03-01 | PHASE4 |
| NCT01225172 | Bristol-Myers Squibb|Mayo Clinic | Breast Cancer | 2010-12-31 | PHASE2 |
| NCT04158362 | UNICANCER | Cancer Metastatic | 2020-06-11 | PHASE3 |
| NCT02455154 | Shanghai Jiao Tong University School of Medicine | Breast Cancer|Osteoporosis | 2015-05 | PHASE2 |
| NCT05918718 | Tehran University of Medical Sciences | Ectopic Pregnancy | 2023-01-20 | PHASE1|PHASE2 |
| NCT07019363 | Fudan University | Breast Cancer|Adjuvant Therapy | 2025-06-15 | PHASE3 |
| NCT01367652 | Roxane Laboratories | Breast Cancer | 2008-03 | PHASE1 |
| NCT04331197 | Cairo University | Subfertility | 2020-05-01 | PHASE4 |
| NCT02692755 | Georgetown University|University of Chicago|Thomas Jefferson University | Hormone Receptor Positive HER-2 Negative Breast Cancer | 2016-09 | PHASE2|PHASE3 |
| NCT06913075 | Indira IVF Hospital Pvt Ltd | Adenomyosis | 2026-06-25 | NA |
| NCT01105312 | Alliance for Clinical Trials in Oncology|National Cancer Institute (NCI) | Breast Cancer | 2010-09 | PHASE1|PHASE2 |
| NCT02188550 | Sinai Hospital of Baltimore | Ovarian Cancer|Endometrial Cancer | 2014-06 | PHASE2 |
| NCT01046578 | University of Saskatchewan|Canadian Institutes of Health Research (CIHR) | Fertility | 2010-01 | PHASE4 |
| NCT00161291 | University of Alabama at Birmingham|Genentech, Inc. | Breast Cancer | 2005-06 | PHASE2 |
| NCT05206448 | Rachel Mejia|Society for Reproductive Investigation|American Society for Reproductive Medicine|University of Wisconsin, Madison | Polycystic Ovary Syndrome|PCOS|Infertility | 2020-10-26 | PHASE4 |
| NCT01430585 | Pfizer | Early Breast Cancer (Phase 2)|Advanced Breast Cancer (Phase 1b) | 2012-03 | PHASE2 |
| NCT02482740 | Buddhist Tzu Chi General Hospital|Chang Gung Memorial Hospital|Chung Shan Medical University|China Medical University Hospital|National Cheng-Kung University Hospital|Kaohsiung Medical University Chung-Ho Memorial Hospital|Kaohsiung Veterans General Hospital.|Ministry of Science and Technology, Taiwan | Uterine Cervical Neoplasms | 2015-05 | PHASE2 |
| NCT03900884 | Peter MacCallum Cancer Centre, Australia | Breast Neoplasm Female | 2019-09-25 | PHASE1 |
| NCT04486352 | Alliance Foundation Trials, LLC.|Genentech, Inc.|Foundation Medicine|Pfizer|Eli Lilly and Company | Endometrial Cancer | 2021-10-20 | PHASE1|PHASE2 |
| NCT00050011 | Novartis Pharmaceuticals | Breast Neoplasms|Osteoporosis | 2002-09 | PHASE3 |
| NCT01642186 | Memorial Sloan Kettering Cancer Center|Fibrolamellar Cancer Foundation|Dana-Farber Cancer Institute|Johns Hopkins University|University of California, San Francisco|Abbott|Novartis Pharmaceuticals | Fibrolamellar Carcinoma|Fibrolamellar Liver Cancer | 2012-07-12 | PHASE2 |
| NCT03400683 | Cairo University | Induction of Abortion | 2018-01 | NA |
| NCT01870505 | Memorial Sloan Kettering Cancer Center|Novartis Pharmaceuticals | Metastatic or Locally-advanced Unresectable Breast Cancer | 2013-05 | PHASE1 |
| NCT05891093 | Fudan University | Breast Cancer | 2023-06-01 | PHASE3 |
| NCT06016738 | Olema Pharmaceuticals, Inc. | Breast Cancer|Advanced Breast Cancer|Metastatic Breast Cancer|ER Positive Breast Cancer|HER2 Negative Breast Carcinoma | 2023-11-16 | PHASE3 |
| NCT02679755 | Pfizer | Breast Cancer | 2016-03-09 | PHASE4 |
| NCT06379113 | Xiaojun Chen | Endometrial Neoplasms|Atypical Endometrial Hyperplasia|Progesterone Resistance|Obesity | 2022-07-13 | PHASE2|PHASE3 |
| NCT04666805 | First Hospital of China Medical University|The First Hospital of Jilin University|Second Hospital of Jilin University|Jilin Provincial Tumor Hospital|Affiliated Zhongshan Hospital of Dalian University|The First Affiliated Hospital of Dalian Medical University|China-Japan Union Hospital, Jilin University|The Second Affiliated Hospital of Dalian Medical University|The Fifth People´s Hospital of Shenyang|General Hospital of Benxi Steel & Iron (Group) Co., Ltd|Affiliated Hospital of Hebei University of Engineering|Fourth People´s Hospital of Shenyang | Breast Cancer | 2020-07-01 | |
| NCT03906669 | St Vincent´s Hospital | Early-stage Breast Cancer|Hormone Receptor Positive Tumor | 2018-03-20 | PHASE2 |
| NCT03306472 | Cambridge University Hospitals NHS Foundation Trust|Anticancer Fund, Belgium | Breast Cancer | 2017-07-20 | PHASE2 |
| NCT04524728 | Istituti Clinici Scientifici Maugeri SpA | Breast|Neoplasm Malignant|Female | 2016-12 | |
| NCT06760637 | Pfizer | Breast Cancer | 2025-01-06 | PHASE3 |
| NCT06394804 | Memorial Sloan Kettering Cancer Center|Verastem, Inc. | Low-Grade Serous Ovarian Cancer | 2024-04-29 | PHASE2 |
| NCT00238316 | NCIC Clinical Trials Group | Breast Cancer | 2000-12-05 | PHASE2 |
| NCT05780567 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Breast Cancer | 2023-03-30 | PHASE3 |
| NCT01686828 | University of Washington | Insulin Resistance|Type 2 Diabetes Mellitus|Obesity|Androgen Deficiency|Metabolic Disease | 2013-06 | PHASE1|PHASE2 |
| NCT05645536 | Tolmar Inc. | Breast Cancer | 2022-12-28 | PHASE3 |
| NCT06072781 | Verastem, Inc.|GOG Foundation|European Network of Gynaecological Oncological Trial Groups (ENGOT)|Australia New Zealand Gynaecological Oncology Group|Korean Gynecologic Oncology Group | Low Grade Serous Ovarian Cancer | 2024-03-18 | PHASE3 |
| NCT00237211 | Novartis Pharmaceuticals|Chugai Pharmaceutical | Postmenopausal Women With Advanced Breast Cancer | 2001-06 | PHASE2 |
| NCT05523609 | Tanta University | Breast Cancer | 2022-11-01 | PHASE2|PHASE3 |
| NCT04217265 | Cairo University | Missed Abortion | 2020-01-05 | PHASE4 |
| NCT03128619 | Jonsson Comprehensive Cancer Center|Bayer|Translational Research in Oncology-U.S. Inc. (TRIO-US) | Estrogen Receptor Positive|HER2+Neu Negative|Invasive Breast Carcinoma|Multifocal Breast Carcinoma|Postmenopausal|Progesterone Receptor Positive|Stage I Breast Cancer|Stage IA Breast Cancer|Stage IB Breast Cancer|Stage II Breast Cancer|Stage IIA Breast Cancer|Stage IIB Breast Cancer|Stage III Breast Cancer|Stage IIIA Breast Cancer|Stage IIIB Breast Cancer|Stage IIIC Breast Cancer|Stage IV Breast Cancer | 2017-08-02 | PHASE1 |
| NCT04546009 | Hoffmann-La Roche | Estrogen Receptor-Positive, HER2-Negative Locally Advanced or Metastatic Breast Cancer | 2020-10-09 | PHASE3 |
| NCT00003140 | NCIC Clinical Trials Group|National Cancer Institute (NCI)|North Central Cancer Treatment Group|ETOP IBCSG Partners Foundation|Eastern Cooperative Oncology Group|SWOG Cancer Research Network|Cancer and Leukemia Group B|European Organisation for Research and Treatment of Cancer - EORTC | Breast Cancer | 1998-08-24 | PHASE3 |
| NCT00728949 | Eli Lilly and Company | Metastatic Breast Cancer | 2008-08 | PHASE2 |
| NCT01958021 | Novartis Pharmaceuticals | Advanced, Metastatic Breast Cancer | 2013-12-17 | PHASE3 |
| NCT06181305 | Rahem Fertility Center | IVF | 2024-02-24 | PHASE4 |
| NCT04603183 | MedSIR|Eli Lilly and Company | Breast Cancer Metastatic | 2021-06-02 | PHASE2 |
| NCT05638594 | Shengjing Hospital | Breast Cancer | 2022-12-20 | PHASE2 |
| NCT01693289 | Zagazig University | Focus of Study | 2012-01 | PHASE1 |
| NCT02214004 | Gangnam Severance Hospital|Seoul National University Hospital|Severance Hospital|Samsung Medical Center|Asan Medical Center | Breast Cancer | 2015-03 | PHASE2 |
| NCT06403488 | Beni-Suef University | Polycystic Ovary Syndrome | 2023-10-01 | PHASE3 |
| NCT02647424 | The University of Hong Kong | Polycystic Ovarian Syndrome|Subfertility | 2015-12 | NA |
| NCT05464810 | Emory University|National Cancer Institute (NCI) | Anatomic Stage I Breast Cancer AJCC v8|Anatomic Stage II Breast Cancer AJCC v8|Anatomic Stage III Breast Cancer AJCC v8|HER2-Negative Breast Carcinoma|Hormone Receptor-Positive Breast Carcinoma|Invasive Breast Carcinoma | 2022-09-02 | EARLY_PHASE1 |
| NCT01797718 | Helsinki University Central Hospital|Foundation for Paediatric Research, Finland | Constitutional Delay of Growth and Puberty | 2013-10 | PHASE2|PHASE3 |
| NCT02918084 | IRCCS Azienda Ospedaliera Universitaria San Martino - IST Istituto Nazionale per la Ricerca sul Cancro, Genoa, Italy|Clinical Research Technology S.r.l. | Breast Cancer | 2013-06 | PHASE3 |
| NCT02005887 | ETOP IBCSG Partners Foundation | Breast Cancer Invasive Nos | 2014-02 | PHASE2 |
| NCT03054363 | University of Colorado, Denver|Pfizer|Cascadian Therapeutics Inc.|Criterium, Inc. | Breast Cancer | 2017-11-27 | PHASE1|PHASE2 |
| NCT02246621 | Eli Lilly and Company | Breast Cancer | 2014-11-06 | PHASE3 |
| NCT05181033 | National University Hospital, Singapore|Eisai Co., Ltd. | Breast Cancer | 2021-12-27 | PHASE2 |
| NCT00856050 | Dana-Farber Cancer Institute|Brigham and Women´s Hospital|Novartis | Leiomyosarcoma | 2009-02 | PHASE2 |
| NCT00804960 | Center for Human Reproduction | Infertility | 2008-09 | PHASE4 |
| NCT05874518 | Liuzhou Maternity and Child Healthcare Hospital | Warm Needling|Electroacupuncture|Ovulation Dysfunction | 2021-12-01 | NA |
| NCT03628066 | NSABP Foundation Inc|Genomic Health?, Inc.|Pfizer | Breast Cancer | 2018-10-22 | PHASE2 |
| NCT02499146 | Pfizer | Advanced Breast Cancer | 2015-09-11 | PHASE1 |
| NCT07305246 | First Hospital of China Medical University|Liaoning Cancer Hospital & Institute | Breast Cancer | 2025-12 | PHASE2 |
| NCT02291913 | SCRI Development Innovations, LLC|Novartis | Breast Cancer | 2014-12-18 | PHASE2 |
| NCT02730091 | Centre Hospitalier Universitaire de Besancon|Pierre Fabre Medicament | Breast Cancer | 2016-02-24 | PHASE3 |
| NCT02630485 | University of British Columbia | Polycystic Ovary Syndrome|Infertility | 2015-12 | NA |
| NCT06507618 | University of Virginia | Breast Cancer Female | 2024-07-19 | PHASE3 |
| NCT04872608 | Memorial Sloan Kettering Cancer Center|Context Therapeutics Inc. | Metastatic Breast Cancer|Unresectable Breast Cancer | 2021-09-09 | PHASE1 |
| NCT07492394 | Hebei Medical University Fourth Hospital|Jiangsu Hengrui Pharmaceutical Co., Ltd. | Breast Cancer | 2025-09-12 | PHASE2 |
| NCT05768139 | Eli Lilly and Company | Breast Cancer|Solid Tumors, Adult | 2023-04-17 | PHASE1|PHASE2 |
| NCT00237198 | Novartis Pharmaceuticals|Chugai Pharmaceutical | Postmenopausal Women With Advanced Breast Cancer | 2004-03 | PHASE2 |
| NCT02010021 | Dartmouth-Hitchcock Medical Center | Breast Cancer | 2014-01 | NA |
| NCT04176354 | Pfizer | Metastatic Breast Cancer | 2019-01-25 | |
| NCT01231659 | Novartis Pharmaceuticals | Postmenopausal Women|Locally Advanced Metastatic Breast Cancer|Metastatic Breast Cancer | 2011-08-09 | PHASE2 |
| NCT03439046 | Novartis Pharmaceuticals | Breast Cancer | 2018-02-02 | PHASE3 |
| NCT05463601 | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University|Jiangsu HengRui Medicine Co., Ltd. | Metastatic Breast Cancer | 2022-08-01 | PHASE2 |
| NCT00338728 | M.D. Anderson Cancer Center|National Cancer Institute (NCI) | Anatomic Stage IV Breast Cancer AJCC v8|Estrogen Receptor Positive|KIT Positive|PDGFR Positive|Postmenopausal|Progesterone Receptor Positive|Prognostic Stage IV Breast Cancer AJCC v8 | 2003-10-03 | PHASE2 |
| NCT02549430 | Fondazione Sandro Pitigliani | Breast Cancer | 2012-10 | PHASE2 |
| NCT05952557 | AstraZeneca|Austrian Breast & Colorectal Cancer Study Group | Breast Cancer, Early Breast Cancer | 2023-10-05 | PHASE3 |
| NCT04985266 | Royal Marsden NHS Foundation Trust|Pfizer|AstraZeneca|Institute of Cancer Research, United Kingdom|UNICANCER|Gustave Roussy, Cancer Campus, Grand Paris|Invitae Corporation | ER&addition; Breast Cancer|HER2-negative Breast Cancer | 2022-03-30 | PHASE2 |
| NCT02344472 | Prof. Wolfgang Janni|Roche Pharma AG|Novartis Pharmaceuticals|Eisai GmbH|Celgene Corporation | Metastatic Breast Cancer | 2015-09 | PHASE3 |
| NCT04272801 | Shayna Showalter, MD|National Cancer Institute (NCI) | Breast Cancer Female | 2020-04-07 | PHASE2 |
| NCT02900105 | KK Women´s and Children´s Hospital | Azoospermia, Nonobstructive|Oligozoospermia | 2015-02 | PHASE3 |
| NCT05161195 | Novartis Pharmaceuticals | Metastatic Breast Cancer | 2022-07-07 | PHASE4 |
| NCT03378297 | Haukeland University Hospital | Ovarian Cancer | 2018-05-04 | EARLY_PHASE1 |
| NCT05809024 | Yongsheng Wang|Jiangsu HengRui Medicine Co., Ltd. | Locally Advanced Breast Cancer|Hormone Receptor Positive?HER2-negative Breast Cancer | 2023-03-01 | PHASE4 |
| NCT01814449 | Fudan University | Breast Cancer|Hypoxia | 2012-03 | |
| NCT01064635 | IRCCS Azienda Ospedaliera Universitaria San Martino - IST Istituto Nazionale per la Ricerca sul Cancro, Genoa, Italy | Breast Cancer | 2005-08 | PHASE3 |
| NCT00611715 | Vanderbilt-Ingram Cancer Center|National Cancer Institute (NCI) | Breast Cancer | 2003-11 | PHASE2 |
| NCT07061717 | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | Hormone Receptor-Positive and HER2-Negative Advanced Breast Cancer | 2025-07-01 | PHASE3 |
| NCT00541086 | Gruppo Italiano Mammella (GIM) | Breast Cancer | 2007-03 | PHASE3 |
| NCT00004205 | ETOP IBCSG Partners Foundation|UNICANCER|Danish Breast Cancer Cooperative Group | Breast Cancer | 1998-03 | PHASE3 |
| NCT00911313 | Mansoura University | Polycystic Ovary Syndrome | 2006-06 | NA |
| NCT00248170 | Novartis Pharmaceuticals | Breast Cancer | 2005-12 | PHASE3 |
| NCT03096847 | Novartis Pharmaceuticals | Advanced Metastatic Breast Cancer | 2016-10-24 | PHASE3 |
| NCT06790693 | Hoffmann-La Roche | Breast Cancer | 2025-04-09 | PHASE3 |
| NCT00247650 | Novartis | Breast Cancer | 2005-09 | PHASE2 |
| NCT06418347 | Ain Shams University | Polycystic Ovary Syndrome|Infertility, Female | 2024-04-01 | PHASE3 |
| NCT00171314 | Novartis Pharmaceuticals | Breast Cancer | 2004-03 | PHASE3 |
| NCT07389733 | Shandong Suncadia Medicine Co., Ltd. | Advanced Unresectable or Metastatic Breast Cancer of Adults | 2026-03-27 | PHASE1|PHASE2 |
| NCT00999804 | Baylor Breast Care Center|Translational Breast Cancer Research Consortium|GlaxoSmithKline | Breast Cancer | 2011-10 | PHASE2 |
| NCT06905301 | Novartis Pharmaceuticals | Breast Cancer | 2026-01-23 | |
| NCT04735367 | Pfizer | Breast Cancer | 2021-02-03 | |
| NCT02228681 | GOG Foundation|Novartis Pharmaceuticals | Advanced, Persistent, or Recurrent Endometrial Cancer | 2015-05-21 | PHASE2 |
| NCT02941926 | Novartis Pharmaceuticals | Breast Cancer | 2016-11-30 | PHASE3 |
| NCT01367626 | Roxane Laboratories | Breast Cancer | 2008-03 | PHASE1 |
| NCT05207709 | SOLTI Breast Cancer Research Group|Novartis|Alliance Foundation Trials, LLC. | Metastatic Breast Cancer | 2022-03-28 | PHASE3 |
| NCT00648063 | Mylan Pharmaceuticals Inc | Healthy | 2005-11 | PHASE1 |
| NCT03058939 | University of Chicago | Breast Cancer|Breast Cancer Stage II|Breast Cancer Stage III | 2018-11 | PHASE2 |
| NCT04720807 | Xinhua Hospital, Shanghai Jiao Tong University School of Medicine | Platinum-resistant Recurrent Ovarian Cancer | 2020-09-01 | PHASE2 |
| NCT00375752 | Novartis Pharmaceuticals | Breast Neoplasms | 2006-06-01 | PHASE4 |
| NCT01684215 | Pfizer | Neoplasms|Breast Neoplasms | 2012-10-19 | PHASE2 |
| NCT04258163 | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University|Sun Yat-sen University|First People´s Hospital of Foshan | Metastatic Breast Cancer | 2019-01-01 | |
| NCT06243185 | Fengzhi Feng | Recurrent Ovarian Carcinoma | 2023-11-17 | PHASE2 |
| NCT04593108 | Dr.Dalia Mohammed Al Sayed Zaki|Benha University | Missed Abortion | 2019-01-15 | |
| NCT02538484 | The University of Texas Health Science Center at San Antonio | Breast Cancer | 2016-04 | EARLY_PHASE1 |
| NCT02703649 | Mount Sinai Hospital, Canada | Anovulation | 2016-03 | PHASE4 |
| NCT03008408 | M.D. Anderson Cancer Center | Recurrent Endometrial Carcinoma|Recurrent Endometrial Endometrioid Adenocarcinoma|Refractory Endometrial Carcinoma|Refractory Endometrial Endometrioid Adenocarcinoma|Stage III Uterine Corpus Cancer AJCC v8|Stage IIIA Uterine Corpus Cancer AJCC v8|Stage IIIB Uterine Corpus Cancer AJCC v8|Stage IIIC Uterine Corpus Cancer AJCC v8|Stage IIIC1 Uterine Corpus Cancer AJCC v8|Stage IIIC2 Uterine Corpus Cancer AJCC v8|Stage IV Uterine Corpus Cancer AJCC v8|Stage IVA Uterine Corpus Cancer AJCC v8|Stage IVB Uterine Corpus Cancer AJCC v8 | 2017-08-18 | PHASE2 |
| NCT04049227 | Northwestern University|National Cancer Institute (NCI) | Endometrial Endometrioid Adenocarcinoma | 2019-08-12 | EARLY_PHASE1 |
| NCT01553903 | Institut Claudius Regaud | Breast Cancer | 2011-12 | PHASE4 |
| NCT03644186 | ETOP IBCSG Partners Foundation|Pfizer|Hoffmann-La Roche | Breast Cancer|Estrogen Receptor Positive Tumor|HER2-positive Breast Cancer | 2019-04-16 | PHASE2 |
| NCT03540979 | Meir Medical Center | Reproductive Behavior | 2018-06 | NA |
| NCT05304273 | Calcutta National Medical College and Hospital | Miscarriage | 2022-05-05 | PHASE3 |
| NCT07160855 | Nishtar Medical University | Miscarriage in First Trimester|Missed Miscarriage | 2025-05-13 | PHASE4 |
| NCT00530868 | University of Alabama at Birmingham|Genentech, Inc.|Breast Cancer Research Foundation | Breast Cancer|Cancer of the Breast|Breast Neoplasm | 2007-10-08 | PHASE2 |
| NCT02152943 | M.D. Anderson Cancer Center|National Cancer Institute (NCI) | Advanced Malignant Solid Neoplasm|Estrogen Receptor Positive|HER2+Neu Positive|Postmenopausal|Premenopausal|Progesterone Receptor Positive|Recurrent Breast Carcinoma|Refractory Breast Carcinoma|Refractory Hormone Receptor Positive Breast Carcinoma|Stage IIIA Breast Cancer AJCC v7|Stage IIIB Breast Cancer AJCC v7|Stage IIIC Breast Cancer AJCC v7|Stage IV Breast Cancer AJCC v6 and v7 | 2014-07-17 | PHASE1 |
| NCT00382070 | NSABP Foundation Inc|National Cancer Institute (NCI)|Novartis | Breast Cancer | 2006-08 | PHASE3 |
| NCT02470741 | University of California, San Francisco | Leiomyoma|Uterine Fibroids | 2015-07 | PHASE4 |
| NCT00601900 | National Cancer Institute (NCI) | Invasive Breast Carcinoma|Recurrent Breast Carcinoma|Stage III Breast Cancer AJCC v6|Stage IV Breast Cancer AJCC v6 and v7 | 2008-09-24 | PHASE3 |
| NCT00796107 | Hoffmann-La Roche | Breast Cancer | 2009-01-28 | PHASE2 |
| NCT00902954 | Fudan University | Breast Cancer | 2008-03 | PHASE3 |
| NCT02296801 | NSABP Foundation Inc|Pfizer|Royal Marsden NHS Foundation Trust|Institute of Cancer Research, United Kingdom | Breast Cancer|Breast Carcinoma|Breast Tumors | 2015-01 | PHASE2 |
| NCT03625531 | Hongxia Ma | Polycystic Ovary Syndrome | 2018-08-13 | PHASE3 |
| NCT01068249 | M.D. Anderson Cancer Center|Novartis | Endometrial Cancer | 2010-04-30 | PHASE2 |
| NCT03633331 | Alliance for Clinical Trials in Oncology|National Cancer Institute (NCI) | Estrogen Receptor-positive Breast Cancer|HER2+Neu Negative|Stage IV Breast Cancer AJCC v6 and v7 | 2018-08-15 | PHASE2 |
| NCT01232075 | Cairo University|Ahmed Elgazzar Hospital | Infertility | 2008-09 | PHASE2 |
| NCT00681928 | City of Hope Medical Center|National Cancer Institute (NCI) | Breast Cancer | 2007-10 | |
| NCT04488107 | Ahon Pharmaceutical Co., Ltd.|Fudan University|Zhejiang Cancer Hospital|Sir Run Run Shaw Hospital | Breast Neoplasms | 2019-02-14 | PHASE1|PHASE2 |
| NCT07319429 | Fudan University | Endometrial Cancer|Fertility | 2026-01-25 | PHASE2|PHASE3 |
| NCT00949598 | Institut du Cancer de Montpellier - Val d´Aurelle | Breast Cancer | 2008-12 | PHASE3 |
| NCT00610077 | Sun Pharmaceutical Industries Limited | Infertility | 2004-12 | PHASE3 |
| NCT03555877 | GBG Forschungs GmbH | Breast Cancer Metastatic | 2018-03-15 | PHASE2 |
| NCT00721409 | Pfizer | Breast Cancer | 2008-09-15 | PHASE2 |
| NCT03628625 | Ain Shams Maternity Hospital | Miscarriage|Missed Abortion | 2018-09-10 | PHASE2 |
| NCT03691493 | Emory University|Pfizer|National Cancer Institute (NCI)|National Institutes of Health (NIH) | Anatomic Stage IV Breast Cancer AJCC v8|Estrogen Receptor Positive|HER2+Neu Negative|Metastatic Breast Carcinoma|Metastatic Malignant Neoplasm in the Bone|Progesterone Receptor Positive|Prognostic Stage IV Breast Cancer AJCC v8 | 2019-02-08 | PHASE2 |
| NCT00573755 | Mayo Clinic|National Cancer Institute (NCI) | Breast Cancer | 2007-12 | PHASE2 |
| NCT04987632 | Qiu-ping Lin | PCOS|Infertility, Female | 2021-08-03 | PHASE1 |
| NCT06452719 | University of Pennsylvania | Early Pregnancy Loss|Miscarriage in First Trimester|Miscarriage | 2024-08-22 | PHASE2 |
| NCT00199134 | Jules Bordet Institute|Feculdade de Medicina da Universidade de Sao Paulo - Brasil|Hospital de Clinicas de Porto Alegre|Hospital do Cancer, Sao Paulo | Breast Cancer | 2004-11 | PHASE2 |
| NCT04002635 | CRG UZ Brussel|University Hospital, Ghent | Infertility, Female|Polycystic Ovary Syndrome|IVF|Ovulation Disorder | 2020-12-01 | PHASE4 |
| NCT06630325 | OHSU Knight Cancer Institute|Oregon Health and Science University|Eli Lilly and Company|AstraZeneca | Advanced Breast Carcinoma|Advanced Malignant Solid Neoplasm|Advanced Ovarian Carcinoma|Advanced Pancreatic Carcinoma|Advanced Prostate Carcinoma|Advanced Sarcoma|Anatomic Stage III Breast Cancer AJCC v8|Anatomic Stage IV Breast Cancer AJCC v8|Stage III Ovarian Cancer AJCC v8|Stage III Pancreatic Cancer AJCC v8|Stage III Prostate Cancer AJCC v8|Stage IV Ovarian Cancer AJCC v8|Stage IV Pancreatic Cancer AJCC v8|Stage IV Prostate Cancer AJCC v8 | 2025-06-24 | PHASE2 |
| NCT06957379 | CSPC ZhongQi Pharmaceutical Technology Co., Ltd. | HR&addition;+HER2- Advanced+Metastatic Breast Cancer | 2024-02-29 | PHASE2 |
| NCT05131893 | National Institute of Oncology, Hungary | Breast Cancer | 2022-03 | |
| NCT01791478 | Vanderbilt-Ingram Cancer Center|National Cancer Institute (NCI) | Estrogen Receptor-positive Breast Cancer|HER2-negative Breast Cancer|Invasive Ductal Breast Carcinoma|Progesterone Receptor-positive Breast Cancer|Recurrent Breast Cancer|Stage IV Breast Cancer | 2013-04 | PHASE1 |
| NCT04393285 | Gynecologic Oncology Group|Eli Lilly and Company | Endometrial Cancer | 2020-10-10 | PHASE2 |
| NCT03913234 | Yonsei University | HER2-positive Breast Cancer|Postmenopausal|Metastatic Breast Cancer | 2019-06-10 | PHASE1|PHASE2 |
| NCT06607601 | Aetion, Inc.|AbbVie|Amgen|AstraZeneca|Bayer|Gilead Sciences|Janssen, LP|Pfizer | Metastatic Breast Cancer | 2010-02-01 | |
| NCT06380751 | AstraZeneca | Advanced Breast Cancer | 2024-08-01 | PHASE3 |
| NCT00241046 | Novartis Pharmaceuticals | Metastatic Breast Cancer | 2002-04 | PHASE4 |
| NCT06426979 | Zagazig University | Pregnancy Tubal | 2023-01-01 | NA |
| NCT03007979 | Washington University School of Medicine|Pfizer | Breast Cancer|Breast Carcinoma|Cancer of Breast|Malignant Tumor of Breast | 2017-06-15 | PHASE2 |
| NCT02980965 | Fudan University | Breast Cancer Female | 2013-05 | PHASE3 |
| NCT05262400 | Pfizer | Breast Cancer|Solid Tumors | 2022-03-14 | PHASE1|PHASE2 |
| NCT03161353 | MedSIR | Breast Cancer | 2017-06-26 | PHASE2 |
| NCT06001762 | Dana-Farber Cancer Institute|Eli Lilly and Company | Breast Cancer|Early-stage Breast Cancer|High Risk Breast Carcinoma | 2023-10-05 | PHASE2 |
| NCT02269670 | Emory University|Novartis | Estrogen Receptor-positive Breast Cancer|HER2-negative Breast Cancer|Progesterone Receptor-positive Breast Cancer|Recurrent Breast Cancer|Stage IIIA Breast Cancer|Stage IIIB Breast Cancer|Stage IIIC Breast Cancer|Stage IV Breast Cancer | 2014-11-25 | PHASE2 |
| NCT03238703 | Fred Hutchinson Cancer Center|National Cancer Institute (NCI) | HER2+Neu Negative|Invasive Breast Carcinoma|Postmenopausal|Stage 0 Breast Cancer|Stage IA Breast Cancer | 2018-09-01 | PHASE4 |
| NCT06486870 | Cairo University | PCOS (Polycystic Ovary Syndrome) of Bilateral Ovaries | 2020-01-01 | PHASE3 |
| NCT03925233 | Xijing Hospital | Breast Cancer Organoids | 2019-01-02 | |
| NCT05035836 | M.D. Anderson Cancer Center|Zymeworks BC Inc. | Breast Cancer|HER2-positive | 2021-11-16 | PHASE2 |
| NCT04469764 | Jonsson Comprehensive Cancer Center|Eli Lilly and Company | Recurrent Endometrial Carcinoma|Recurrent Fallopian Tube Carcinoma|Recurrent Ovarian Carcinoma|Recurrent Primary Peritoneal Carcinoma | 2020-10-16 | PHASE2 |